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ABSTRACT
AMP-ACTIVATED PROTEIN KINASE REGULATION OF MYELOID ANTIGEN
PRESENTING CELL ACTIVITY
Kelly Casey Carroll
December 6, 2013
Inflammatory and metabolic processes are critical to the survival of multicellular
organisms. Inflammation and metabolism are closely linked, and many pathologies are
associated with dysregulation of both of these processes, including obesity, cancer,
diabetes, and atherosclerosis. Understanding the mechanistic links of inflammation and
metabolism are critical for the development of treatments of metabolic and inflammatory
diseases.
AMP-activated protein kinase, AMPK, is a serine/threonine kinase that regulates
energy homeostasis and metabolic stress in eukaryotes. When cellular ATP is low,
AMPK is activated and turns off ATP-consuming anabolic pathways and turns on ATPgenerating catabolic pathways. Previous work from our laboratory, as well as by others,
has provided evidence that AMPKα1 acts as a negative regulator of TLR-induced
inflammatory function. The goal of this dissertation was to investigate the role of
AMPKα1 in myeloid antigen presenting cell activity.
Herein we demonstrate that AMPKα1-deficient macrophages and dendritic cells
(DCs) exhibit heightened inflammatory function and an enhanced capacity for antigen
presentation favoring the promotion of Th1 and Th17 responses. Macrophages and DCs
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generated from AMPKα1-deficient mice produced higher levels of proinflammatory
cytokines and decreased production of the anti-inflammatory cytokine IL-10 in response
to both TLR and CD40 stimulation as compared to AMPKα1+/+ cells. In assays of
antigen presentation, AMPKα1 deficiency in both the myeloid APC and T cell
populations contributed to enhanced IL-17 and IFNγ production. Focusing on the
CD154-CD40 interaction, we found that CD40 stimulation resulted in increased
phosphorylation of ERK1/2, p38, and NF-κB p65 and decreased activation of the antiinflammatory Akt - GSK3β - CREB pathway in DCs deficient for AMPKα1. AMPKα1
serves to attenuate LPS and CD40-mediated proinflammatory activity of myeloid APC
and AMPKα1 activity in both APC and T cells antagonizes the development of
proinflammatory T cell responses during antigen presentation.
Additionally, we sought to investigate the influence of macrophage-expressed
AMPKα1 on tumor-macrophage interactions and macrophage polarization in the tumor
microenvironment. Our studies show that macrophage-expressed AMPKα1 polarizes
tumor-infiltrating macrophages (TIMs) to an anti-inflammatory phenotype and
contributes to tumor growth. To evaluate the role of myeloid cell-expressed AMPKα1 in
tumor growth and metastasis, we used an AMPKα1 Cre-lox transgenic mouse model.
AMPKα1flox/flox LysM-Cre+ (described subsequently as MacAMPKα1 KO) mice had
reduced Lewis lung carcinoma (LLC) tumor growth and metastasis compared to
AMPKα1flox/- LysM-Cre- (WT) mice. Additionally, TIMs isolated from MacAMPKα1
KO mice exhibited higher production of proinflammatory cytokines and matrix
metalloproteinases (MMPs). Furthermore, TIMs isolated from MacAMPKα1 KO mice
had higher phosphorylation of p65 NF-κB and reduced phosphorylation of Akt and
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CREB. Overall, deficiency of myeloid AMPKα1 results in higher proinflammatory
activity of TIMs and decreased tumor growth.
Our studies herein demonstrate that AMPKα1 counter-regulates myeloid cell
TLR- and CD154-induced inflammatory activity and antagonizes the development of
proinflammatory effector T cell responses. Furthermore, myeloid-expressed AMPKα1
contributes to the polarization of TIMs to an anti-inflammatory phenotype and leads to
increased tumor growth and metastasis. These studies demonstrate that AMPKα1 is an
important link to inflammation and metabolism and is a valuable potential target for the
treatment of inflammatory and metabolic diseases. Additionally, these studies provide
evidence that activation of AMPKα1 in cancer therapy may contribute to increased tumor
growth through polarization of TIMs to an anti-inflammatory phenotype, a valuable
observation given that many AMPK activators are being studied as cancer therapeutics.
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CHAPTER 1
INTRODUCTION

In order to survive and grow, living organisms must maintain energy balance
through regulation of consumption and generation of ATP. The AMP-activated protein
kinase (AMPK) has been well-established as a regulator of energy homeostasis in
eukaryotic cells. AMPK becomes activated by stresses causing ATP depletion and, once
activated, works to turn off ATP-consuming anabolic pathways and turn on ATPproducing catabolic pathways (Fig. 1). In recent years, AMPK has been shown to have a
counter-regulatory role in many inflammatory processes [1].

A BRIEF HISTORY OF AMPK
It is estimated that the ancestral form of AMPK emerged at least one billion years
ago [2]. In the early 1970’s, protein kinase activity associated with inactivation of acetylCoA carboxylase (ACC) [3] and 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGR)
[4] were being investigated independently. Early studies of HMGR and ACC had shown
that the kinase activity leading to inactivation of both proteins was activated by AMP and
in 1987, Carling et al., reported that HMGR and ACC were inactivated by the same
protein kinase [5], now known as AMPK. The name AMP-activated protein kinase was
first proposed in 1988 by Munday et al. [6], and in 1994, mammalian AMPK was
successfully purified and sequenced [7, 8].
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Since these initial studies, interest in AMPK as a regulator of cellular energy has
grown significantly. AMPK is ubiquitously expressed in eukaryotic cells and is thought
to have a conserved function as a metabolic sensor in all eukaryotes, mammals, fungi,
and plants. In addition to its role in metabolism, AMPK is now considered an important
player in inflammation and associated pathologies, including cancer, neurogenerative
disease, obesity, and aging [1].

STRUCTURE AND REGULATION OF AMPK
Heterotrimeric structure
AMPK is an obligate heterotrimer, made up of a catalytic α subunit and
regulatory β and γ subunits (Fig. 1). The α and β subunits each have two isoforms (α1,
α2, β1, β2), while the γ subunit has three (γ1, γ2, γ3). Each isoform is encoded by a
separate gene. The subunit genes are named PRKA followed by a subunit identifier (A1,
A2, B1, B2, G1, G2, G3); for example, the gene for the α1 subunit is PRKAA1. The
subunit genes are distributed across five chromosomes—α1 on chromosome 5, α2 and β2
on chromosome 1, β1 and γ1 on chromosome 12, γ2 on chromosome 7, and γ3 on
chromosome 2 [9]. All 12 possible combinations of isoforms can form complexes,
although α1, β1, and γ1 are the predominant isoforms in most cells [10].
AMPK subunits show differential tissue expression and activation. AMPKα1 is
expressed highly in murine adipose tissue, moderately in liver, kidney, heart, and brain,
and lowest in spleen and pancreas. AMPKα2 expression in mice is highest in skeletal
muscle, then in heart, kidney and liver, and very low in lung, brain, adipose, pancreas,
and spleen. The AMPKβ1 subunit is expressed in many tissues, comparable to α1 subunit
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expression, while β2 is most highly expressed in skeletal muscle and heart tissue. The
AMPKγ1 isoform has very widespread expression, while the γ2 isoform is expressed in a
variety of tissues including brain, placenta, and skeletal muscle, and the γ3 isoform is
expressed rarely and mainly in skeletal muscle [9].
It has been well-established that AMPK is activated in response to increases in the
intracellular AMP:ATP ratio. More recently, it was discovered that in addition to AMP,
ADP directly binds to the γ regulatory subunit and thereby induces a conformational
change that promotes AMPK phosphorylation and protects against dephosphorylation [1].
The γ subunit contains two Bateman domains, sequence motifs that serve as nucleotide
binding sites in many mammals and bacterial proteins. In the γ1 subunit, two Bateman
domains assemble head to head to form a flattened disk with four clefts where
nucleotides can bind. Initial studies on the γ subunit indicated that only two molecules of
AMP bind [11], however, it was recently discovered that three of the four clefts in
mammalian AMPKγ1 bind nucleotide [12]. One cleft does not bind nucleotide at all and
another binds AMP very tightly and does not exc hange with ADP or ATP [12]. The
other two sites bind AMP reversibly and competitively with ADP and ATP. Additionally,
structural studies have shown that nucleotides bind such that the adenine moieties are
deep within the binding cavity and the phosphate groups face the exterior and are
partially exposed [13].
Allosteric Regulation of AMPK
AMPK is allosterically activated by 5’-AMP. This mechanism appears very
specific, as only AMP and closely related AMP analogues can activate AMPK
allosterically [1]. AMPK is not allosterically activated by ADP [1]. The presence of ATP
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antagonizes activation by AMP, although ATP is not a direct inhibitor [14]. It is apparent
that the degree of activation by AMP varies and is dependent upon the identity of the γ
isoform present [15]. It is estimated that maximum allosteric activation achieves a 5-fold
induction of AMPK activity, much less than the activation induced by phosphorylation of
Thr172 [1].
Regulation through phosphorylation/dephosphorylation
AMPK activity is primarily regulated through reversible phosphorylation. In
mammals, AMPK is only significantly active after phosphorylation of Thr172, located
within the activation loop of the α subunit (Fig. 1) [16]. Phosphorylation of AMPK can
be mediated by upstream kinases LKB1, CaMKK (calcium/calmodulin-dependent protein
kinase kinase) α and β, or TAK1 (Transforming growth factor-beta (TGFβ)-activated
kinase) [17]. Additionally, AMP and ADP promote phosphorylation of Thr172 and
activation of AMPK [18].
LKB1 is a serine/threonine kinase that directly phosphorylates Thr172 of AMPK
[19-21], and studies of tissue-specific deletion of LKB1 show that it mediates the
majority of AMPK activation [19, 20]. Although LKB1 phosphorylates only AMPKα1
and AMPKα2 in response to energy stress, it has also been shown to phosphorylate
twelve other kinases including those in the MARK, SIK, BRSK, and NUAK families. All
twelve of these kinases are related to AMPK and it is generally thought that there is
crosstalk between AMPK and the AMPK related kinases [22].
It was believed that AMPK was only activated via an AMP-dependent mechanism
until the discovery that CaMKKs, especially CAMKKβ, also phosphorylate AMPK at
Thr172 [23-25]. CaMKKβ phosphorylates AMPK in response to an increase in the

4

intracellular Ca2+ concentration. Unlike LKB1, CaMKKs are tissue restricted and are
mainly found in neurons, T cells and endothelial cells [26-28]. In addition to LKB1 and
CaMKK, MAPKKK family member TAK1 is an upstream activator of AMPK. TAK1
has been found to phosphorylate and activate AMPK in cell-free assays [29], but the
contexts where TAK1 may regulate AMPK phosphorylation of Thr172 in vivo and
whether TAK1 phosphorylation of AMPK involves LKB1 are still being explored [30].
The Thr172 phosphorylation site serves as an on/off switch for AMPK activity.
While phosphorylation induces AMPK activity, dephosphorylation of AMPK leads to
nearly complete inactivation of AMPK and it has been reported that dephosphorylated
AMPK has negligible catalytic activity [31]. Many mammalian serine/threonine
phosphatases have been shown to effectively dephosphorylate Thr172 and inactivate
AMPK. These include PP (phosphoprotein phosphatase) 1, PP2A, and PP2Ca
phosphatases, although it is apparent that the phosphatases involved in the regulation of
AMPK may be dependent on the cell type and/or stimulus to which the cell is responding
[32]. AMP has long been known to protect against dephosphorylation of the Thr172
residue of AMPK. In 2011, it was shown that in addition to AMP, ADP effectively
protects against dephosphorylation of Thr172 [33].
The level of phosphorylation of Thr172 is controlled by the balance of activities
of upstream kinases and protein phosphatases. There is still much to be resolved,
including many of the structural details revealing how AMP allosterically activates
AMPK and, along with ADP, increases phosphorylation and protects against
dephosphorylation of AMPK [34].
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AMPK ACTIVATORS
Many physiological and pharmacological activators of AMPK have been
reported. AMPK is activated by any ATP-depleting cellular stress, including nutrient
deprivation, hypoxia, ischemia, oxidative stress and exercise [35, 36]. Additionally,
AMPK can also be activated independently of cellular energy stress by adipose tissue
hormones leptin and adiponectin. Leptin has been shown to activate AMPKα2 in skeletal
muscle [37], and alternatively, inhibit AMPKα2 activity in the hypothalamus [38].
Adiponectin has been shown to activate AMPK in both peripheral tissues [39] and the
hypothalamus [40]. Additionally, it is apparent that leptin and adiponectin regulation of
AMPK in the hypothalamus mediates appetite [38]. It has also been shown that TCR
stimulation results in activation of AMPK by CaMKK in T cells through a PI3Kindependent pathway [27].
Pharmacological AMPK activators include 5-aminoimidazole-4-carboxamide
ribose (AICAR). AICAR is taken into the cell and converted to ZMP, an AMP analog
that mimics the effects of AMP. As such, AICAR has the ability to activate any AMPsensitive protein, and has been shown to have AMPK-independent effects [41-43].
Metformin and thiazolidinediones (TZDs), both drugs used to treat type II diabetes, are
known AMPK activators [9]. Metformin is an oral biguanide that inhibits gluconeogenic
and lipogenic gene expression in the liver [44], and activates AMPK in an LKB1dependent manner [45]. It is thought that biguanides activate AMPK through mild
inhibition of respiratory chain complex I, inhibiting mitochondrial respiration, and
leading to a decrease in intracellular ATP levels [46]. The specific contribution of AMPK
to the effect seen by metformin treatment, needs to be further elucidated, as one would
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expect that reduction in mitochondrial metabolism would activate a variety of stresssensing pathways [17]. TZDs are insulin sensitizers and work through upregulation of
peroxisome proliferator-activated receptors (PPARs), a group of nuclear receptors [9].
PPARγ is most highly expressed in adipose tissue, but has also been shown to have a
significant role in the maintenance of skeletal muscle insulin resistance [47] and
contributes to hepatic steatosis in liver [48]. TZDs have been shown to activate AMPK in
skeletal muscle cells through increasing the intracellular AMP:ATP ratio [49].
Additionally, a wide variety of plant products, termed xenobiotics, have been
shown to activate AMPK. Resveratrol, a polyphenol found in the skin of red grapes,
activates AMPK. Recently, low concentrations of resveratrol have been shown to lead to
an accumulation of cAMP and activation of Epac1, a cAMP effector protein, which
increases intracellular Ca2+ and activates AMPK via CaMKKβ [50]. In a type I diabetes
mouse model, polyphenols were shown to activate AMPK and lower lipidemia and
inhibit atherosclerosis disease progression [51]. Other xenobiotics that activate AMPK
include egigallocatechin gallate found in green tea, capsaicin found in chili peppers,
quercetin found in many fruits and vegetables, and curcumin found in tumeric. Generally,
it is thought that these xenobiotics activate AMPK through inhibiting the respiratory
chain or ATP synthase and may have evolved to deter insects and plant-eating animals or
pathogens [34].
While metformin, TZDs, and plant-derived compounds are considered indirect
AMPK activators and often work through alteration of the AMP:ATP ratio, there are also
several direct AMPK activators. These include the aforementioned ZMP, along with
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A769661, PT-1, and OSU-53, and while it known that ZMP acts as an AMP mimetic, the
mechanism for many direct activators remains elusive [1].

AMPK REGULATES CARBOHYDRATE, LIPID, AND PROTEIN
METABOLISM
Once active, AMPK mediates many metabolic signaling events that turn off ATPconsuming pathways and turn on ATP-generating pathways (Fig. 1). AMPK plays a
significant role in the metabolism of carbohydrates through regulation of several
downstream effectors. AMPK impacts expression and trafficking of GLUT4, a
transmembrane protein that regulates the uptake of glucose across the plasma membrane
in response to certain stimuli, such as the presence of insulin and muscle activity [52-54].
Constitutive activation of AMPKα1 results in increased glucose uptake in skeletal muscle
cells [55]. AMPK also phosphorylates the insulin receptor substrate 1 (IRS-1) (Ser789),
the most upstream component of the insulin-signaling cascade [56]. Also, AMPK, along
with CREB-regulated transcription coactivator 2 (CRTC2), regulates liver
gluconeogenesis [57]. AMPK phosphorylates glycogen synthase (Ser7) and inhibits its
activity [58, 59]. Mice deficient for AMPKα2 display decreased phosphorylation (Ser7)
of glycogen synthase in skeletal muscle basally and in response to AICAR treatment [59].
Additionally, AMPK coordinates many aspects of lipid metabolism and the
coordination of fat and carbohydrate metabolism. AMPK has a regulatory role in fatty
acid uptake [60] and once fatty acids are taken into the cell, AMPK plays a critical role in
determining if they are directed towards oxidation or storage [9]. AMPK phosphorylates
and inhibits acetyl-CoA carboxylase (ACC) 1 in lipogenic tissues and mediates
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suppression of fatty acid synthesis [2]. AMPK also suppresses fatty acid synthesis
through inhibition of the transcription factor sterol regulatory element binding protein 1c
(SREBP1c), which regulates many genes involved in lipogenesis, including fatty acid
synthase (FAS) (Fig. 1) [61]. AMPK is also involved in regulation of cholesterol
synthesis as it is directly phosphorylates (Ser872) and inhibits HMG-CoA reductase
(HMGR) (Fig. 1), the rate-limiting enzyme for cholesterol synthesis [14, 62].
AMPK regulates protein synthesis through phosphorylation of eukaryote
elongation factor 2 (eEF-2) kinase (Ser398) and results in inhibition of mRNA translation
and peptide elongation [63]. Additionally, AMPK regulates protein synthesis through
inhibiting the mammalian target of rapamycin complex (mTORC) 1 (Fig. 1). AMPK
inhibition of protein synthesis has been demonstrated in skeletal muscle [64], liver [65],
and cardiac muscle [66]. AMPK phosphorylates the tumor suppressor complex tuberous
sclerosis complex (TSC) 2 (Ser1387), which activates the GTPase Rheb and leads to
mTORC1 inhibition [67]. AMPK also inhibits mTORC1 activity through
phosphorylation of raptor at Ser722 and Ser792, which makes it physically unavailable to
the mTOR complex [68]. In addition to suppression of protein synthesis, the mTORC
pathway has been shown to control many other aspects of metabolism, including
regulation of glucose and lipid homeostasis, suggesting that many of the metabolic
effects attributed to AMPK could be mediated by mTORC signaling [9].

DYSREGULATION OF AMPK IN DISEASE
Dysregulation of AMPK signaling is apparent in several diseases. AMPK
regulates many pathways associated with the metabolic syndrome, a combination of
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medical disorders characterized by insulin resistance, type 2 diabetes, cardiovascular
disease, fatty liver disease, and dysregulation of AMPK in obesity is now being
investigated. AMPK activity is reduced in liver, heart, and skeletal muscle of rat and
mouse genetic models of obesity [69-71]. AICAR activation of AMPK leads to increased
glucose uptake and fatty acid oxidation in diabetic obese rodents [72] and humans [73],
suggesting AMPK may be a valid therapeutic target for metabolic syndrome.
Alternatively, in a few studies of human obesity, AMPK expression and activity are not
significantly decreased [74, 75]. Future studies will further clarify the role of AMPK
signaling in obesity and determine if AMPK activation is a valuable therapeutic strategy
to treat metabolic syndrome.
AMPK has a critical role in regulation of ATP use in the heart and is thought to
play a role in cardiovascular disease. Increased AMPK activity leads to increased glucose
uptake [76] and fatty acid oxidation [77] in the heart, and it has been proposed that
AMPK has a protective role against ischemia-reperfusion injury [9]. In myocardial
ischemia, expression of AMPK α1 and α2 is elevated [77].
Studies thus far indicate that AMPK may play a role in aging. It has been well
described that aging results in decreased ability to tolerate metabolic stress and increased
AMPK signaling has been associated with longer lifespan in C. elegans [78]. The role of
AMPK in the aging of higher organisms is not clear. Current studies show mixed results,
as some reports indicate lower expression of AMPK in muscle with aging, while others
report increases or no change in AMPK activity (reviewed in [9]).
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AMPK AND CANCER
LKB1, an upstream activator of AMPK, is a known tumor suppressor. Germline
mutation in LKB1 results in Peutz-Jeghers syndrome (PJS), a rare hereditary disease
characterized by a predisposition of benign and malignant neoplasms in various organs.
PJS patients have a dramatically increased risk of cancer and are affected at relatively
young ages. Although LKB1 mutations are relatively rare in most cancers, LKB1 somatic
inactivation is seen in approximately 30-50% of sporadic lung adenocarcinomas and 19%
of sporadic squamous cell carcinomas [79]. Additionally, it has been shown that LKB1
expression inversely correlates with tumor grade and stage in human endometrial cancers,
indicating that decreased expression of LKB1 may contribute to endometrial cancer
progression [80].
The role of AMPK in the regulation of LKB1 tumor suppressor signaling and its
association with cancer incidence is being investigated. AICAR treatment of MDA-MB231 breast cancer cells decreases proliferation, markers for invasion, and colony
formation [81]. In vivo, AICAR treatment of MDA-MB-231 tumors in nude mice
attenuated tumor growth [81]. AICAR has also been found to decrease the proliferative
capacity of acute lymphoblastic leukemia cells [82].
Much supporting evidence associating AMPK activity and decreased cancer
incidence has been provided by studies with metformin. Diabetic patients treated with
metformin have a nearly 30% reduction in deaths from cancer compared to those
receiving other diabetic therapies [83]. Additionally, metformin treatment significantly
decreased incidence, size, and increased mean latency in mammary adenocarcinomas of
HER-2/neu-positive transgenic mice [84]. In a murine model of tobacco carcinogen-
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induced lung cancer, oral metformin treatment reduced tumor burden by >50% [85].
These studies along with many more concerning breast, prostate, colorectal, pancreatic,
and other malignancies have led to over two dozen clinical trials investigating metformin
as a potential anti-cancer drug [86]. Although the anti-tumorigenic properties of
metformin are often attributed to its activation of the LKB1 pathway and AMPK, it is
known that this pathway is only one of many by which metformin exerts its effects [86,
87]. Thus, it is difficult to attribute the effects of metformin to AMPK activation alone.
AMPK activity may suppress tumor growth through a variety of mechanisms. Tumor
growth requires a great deal of energy and AMPK may reduce cancer cell growth through
inhibition of anabolic pathways in times of limited energy [88].
Alternatively, there is also evidence that AMPK activity promotes tumor growth.
Studies on prostate cancer tissues and cell lines suggest that AMPK inhibition may
benefit prostate cancer patients. ACC phosphorylation and AMPK activity were
increased in malignant prostate tissue compared to normal tissue cells [89]. Reduced
expression of AMPK through siRNA led to decreased proliferation of prostate cancer cell
lines and treatment of prostate cancer lines with a non-selective AMPK inhibitor induced
higher levels of apoptosis [89, 90]. It has been proposed that increased AMPK activity
gives cancer cells a survival advantage, possibly through increasing glucose uptake and
glycolysis, mitosis, and/or migration [1].

AMPK AND INFLAMMATION
Inflammation is crucial to maintaining health. Innate and adaptive immunity
initiate inflammatory processes to offer protection from invading pathogens and repair
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tissue injuries. Although inflammation is crucial to protect and heal, it can be dangerous
if activated in excess or chronically. Chronic inflammation has been shown to play a role
in many diseases, including type II diabetes, atherosclerosis, and cancer [1, 91].
Inflammation and metabolism are closely linked. It is thought that these two
systems coevolved, and in lower organisms such as Drosophila melanogaster both are
regulated by one organ, the fat body [92]. Metabolic dysregulation is associated with
many diseases known to have inflammatory dysregulation, including diabetes,
atherosclerosis, and cancer [93]. Obesity is associated with chronic inflammation and
increased risk of inflammatory disease, and alternatively, malnutrition is associated with
immunosuppression [92]. There are also similarities between adipocytes and
macrophages, as both cell types secrete cytokines and can be activated by pathogen
components like LPS [92]. Additionally, pre-adipocytes can trans-differentiate into
macrophages [92].
It is also apparent that the metabolism of immune cells is closely related to their
inflammatory capacity. Inflammatory cells such as activated macrophages [94] and Th17
cells [94, 95] display high rates of glycolysis and lower rates of oxidative metabolism.
Alternatively, anti-inflammatory macrophages [94] and regulatory T cells (Treg) [94, 95]
have lower rates of glycolysis. It is also apparent that resting DCs generate ATP through
oxidative phosphorylation and upon LPS stimulation, switch to glycolysis [96]. Much
about this association is still unclear, but increased glycolysis may provide a quicker,
albeit less efficient, source of energy for the cell to rapidly alter its functional phenotype
from resting to inflammatory. Interestingly, the transition to glycolysis in activated cells
mirrors the ‘Warburg effect’ previously observed in cancer cells [93].
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AMPK has an established role in regulation of cellular energy metabolism, and
there is a growing number of reports indicating AMPK has a prominent role in the
regulation of inflammation. AMPK activation by AICAR has been shown to reduce the
severity of murine acute and chronic colitis [97], experimental autoimmune
encephalomyelitis (EAE) [98], and experimental autoimmune uveitis (EAU) [43].
Additionally, reports demonstrate that in vitro AICAR treatment inhibits the LPS-induced
inflammatory response [97, 99]. AMPK activation by AICAR has also been shown to
inhibit inducible nitric oxide synthase (iNOS) synthesis in adipocytes, macrophages, and
myocytes [100]. AMPK activation via metformin also decreases inflammation. In mild
metabolic syndrome, metformin reduces systemic inflammation through decreasing the
presence of C-reactive protein and IL-6 [101]. Metformin also reduces macrophage
migration inhibitory factor (MIF) expression in obese people [102]. Metformin is thought
to activate AMPK through decreasing intracellular ATP through inhibition of the
mitochondrial respiratory chain [46], but as previously described, metformin has many
AMPK-independent effects [86, 87] and much regarding its effects on systemic
inflammation is unknown.
Many AMPK activators are also associated with reduced inflammation, including
adiponectin [103], phytochemicals resveratrol and curcumin [104], as well as physical
activity [105]. Additionally, IL-4, PPARγ agonist 15dPJG2, ciglitazone, and the green tea
polyphenol epigallocatechin-3-gallate activate AMPK in macrophages (Suttles
unpublished data).
Studies from our lab using macrophage cell lines expressing constitutively active
(CA) and dominant negative forms (DN) of AMPKα1 indicated that AMPK promotes
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anti-inflammatory activity and suppresses proinflammatory activity in macrophages
[106]. Macrophage cell lines expressing DN AMPKα1 produced higher levels of TNFα
and IL-6 in response to LPS. Furthermore, we demonstrated that treatment of primary
macrophages with anti-inflammatory stimuli such as IL-10 and TGFβ resulted in rapid
phosphorylation of AMPK, whereas LPS stimulation resulted in rapid de-phosphorylation
of AMPK [106]. Subsequent to this work, it was reported that AMPK counter-regulates
lipid-induced inflammation through SIRT1 [107]. It has also been shown that AMPKβ1
reduces adipose tissue macrophage inflammation in obesity [108]. Additionally,
AMPKα1 antagonizes TLR-induced DC maturation [96]. It was also recently shown that
AMPK suppresses IFNγ-induced gene expression in astrocytes and microglia [109].
Studies on mTOR activity in macrophages have provided much insight into the
role of AMPK in myeloid inflammation. AMPK, along with mTOR and SIRT1, has been
shown to regulate autophagy in macrophages [110, 111]. Impairment of autophagy in
macrophages leads to inflammation and has been associated with progression of
atherosclerosis [112].
AMPK has also been shown to play a role in T cell survival [113] and
proliferation [114]. It has also been reported that AMPKα1 is required for CD8+ T cell
memory [115]. In murine models of inflammatory disease, in vivo AICAR treatment
reduced the production of proinflammatory Th cell cytokines [43, 97, 98]. Alternatively,
studies by McIver et al., showed that AMPKα1 regulates T cell viability and metabolism
and promotes CD44 expression and proinflammatory cytokine production through
mTORC1 in CD8+ T cells, but not CD4+ T cells [116]. A study of CD4+ T cell subset
differentiation reported that generation of Treg was accompanied by elevation of AMPK
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activity, associated with dependency on lipid oxidation for the Treg functional phenotype
[37].

MACROPHAGE AND DC FUNCTION AND PLASTICITY
Macrophages and DCs are very heterogeneous and plastic cells. Both are part of
the mononuclear phagocyte system and are generated from myeloid precursors in bone
marrow. Newly formed monocytes leave the bone marrow, enter the blood, and populate
different tissues and can differentiate into macrophages or DCs. Both macrophages and
DCs have subpopulations resident to specific tissues, often given their own names such as
microglial cells in the brain, Langerhans cells in the skin, and Kupffer cells in the liver
[94]. It is currently not clear if all macrophages and DCs derive from a common
progenitor and additionally, there is some controversy over whether the many varied
subsets of macrophages and DCs arise from the same progenitor [117].
Macrophages are present in all tissues of the body and have an astonishing variety
of functional and phenotypic characteristics (Fig. 2). The function and phenotype of a
given macrophage population is thought to be dependent upon the presence of various
factors in its environment, including cytokines, chemokines, adrenergic and cholinergic
agonists, complement proteins, fatty acids, stress hormones, and immunoglobulins [118,
119]. Macrophages in different tissues display quite different functional patterns.
Stimulation by various factors alone or in combination is thought to regulate macrophage
homing to various tissues and function. Macrophages engage in a wide spectrum of
activities and many are in opposition to one another. These include proinflammatory and
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anti-inflammatory activities, immunogenic and tolerogenic activities, and tissuedestructive and tissue-restorative activities [120].
Many have tried to establish subsets of macrophages with distinct phenotypes.
Macrophages are often characterized as classically activated (M1) or alternatively
activated (M2). The M1/M2 nomenclature is derived from the T cell responses associated
with these macrophage phenotypes. Classically activated macrophages are inflammatory
and phagocytic and are associated with Th1 cytokines IFNγ, IL-12, TNFα and toll-like
receptor (TLR) ligands [121]. Inflammatory macrophages have increased activity of
STAT1 and NF-κB transcription factors that up-regulate proinflammatory genes such as
nitric oxide and reactive oxygen species [121, 122]. Classical activation of macrophages
is imperative to proper immune defense against viral and microbial pathogens and cancer,
although proinflammatory activities must be tightly controlled. Dysregulation of
macrophage-induced inflammation has been implicated in many autoimmune diseases,
such as multiple sclerosis [123] and rheumatoid arthritis [124, 125].
Alternatively activated macrophages display a quite different functional pattern
and are generally anti-inflammatory and wound healing (Fig. 2). Alternative activation is
induced by Th2 cytokines IL-4 and IL-13 and leads to production of anti-inflammatory
IL-10, TGFβ, and arginase [126]. Alternatively activated macrophages have many
physiologic and pathological roles and are involved in homeostasis, inflammation, repair,
allergy, parasitic infections, and tumor progression [126, 127]. Wound healing responses
are also associated with vascular endothelial growth factor (VEGF), MMPs, and
epidermal growth factor (EGF) [128]. IL-4 and IL-13 signaling are also associated with
increased expression of PPARγ, a nuclear receptor involved in wound healing and lipid
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metabolism, and reports suggest that PPARγ expression may be involved in alternative
activation of macrophages [128, 129]. Although classical and alternative phenotyping of
macrophages may be helpful in some cases, in others it is limited and does not appreciate
the apparent heterogeneity of macrophages. It is evident that exposure of macrophages to
various stimuli alone or in combination (IL-10, TGFβ, IgG, and many others) leads to
functional phenotypes that are not necessarily entirely classical or alternative [130].
It is also apparent that the macrophage phenotype and response profile is not
static. In 2003, it was reported that macrophage response to LPS changes over time, with
vastly different gene expression early (0-6 h) and late (12-24 h) [131]. It is also clear that
macrophages are continually sensing and responding to stimuli in their
microenvironment. Macrophages may respond to cytokines they produced through earlier
responses and shift their functional phenotype accordingly. In the context of injury,
macrophages contribute early on to the generation of an inflammatory response
(proinflammatory cytokine, antimicrobial oxidative radicals, and tissue-debriding
proteinase production) and later once the wound is cleared of inflammatory debris,
macrophages contribute to wound resolution [122, 130]. Although it has not been
formally established, it is likely that the early inflammatory macrophages and late wound
resolving macrophages are the same population experiencing a progressive change in
their functional phenotype through differential regulation by tissue-derived cytokines,
hormones, and metabolites [120, 130, 132]. An alternative hypothesis is that the switch in
macrophage roles reflects a sequential recruitment of first inflammatory then healing
populations of macrophages [121]. More studies are needed to elucidate the mechanisms
regulating macrophage injury response and resolution.
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Studies in our lab also demonstrated that macrophages revert back to their original
phenotype after cytokine signaling ends. For example, in vitro or in vivo treatment of
macrophages with cytokine changes their functional response to LPS. However, if the
macrophages are washed after cytokine treatment and cultured for 1-2 days without
cytokine, they respond to LPS stimulation identically to macrophages that had no
cytokine stimulation [130]. Additionally, when immature DCs, bone marrow-derived
macrophages, and peritoneal macrophages are removed from IL-4 and GM-CSF and
placed in a neutral environment, they revert back to a basal macrophage phenotype [130,
133]. These studies and others indicate that cytokines induce a transient functional
pattern rather than a stable macrophage subset.
Macrophage populations in various tissues throughout the body (i.e. lung, liver,
peritoneum, brain) are usually considered to be separate lineages with distinct and unique
functions [118, 119]. Early studies indicated that many of these populations were derived
from precursors that seeded organs during development. Since then, however, it has been
shown that the slow turnover of tissue macrophage populations is maintained, at least in
part, by infiltrating monocytes from the blood [118, 119]. Although each of these
populations displays a unique phenotype, usually described by high/low expression of
various cell surface markers, it is apparent that there is still much heterogeneity within
each population. Importantly, each population is also able to alter its phenotype in
response to infection and/or inflammation [118, 119, 134]. These observations have led
many to question how much of the phenotype of a macrophage population is a result of
reversible adaptation to the tissue microenvironment and how much of the phenotype is
due to irreversible differentiation [130].
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DCs are highly specialized APC that efficiently activate T lymphocytes (Fig. 3).
DCs arise from precursors in the blood and home to peripheral non-lymphoid tissues as
immature DCs. Immature DCs sense and sample antigen in their environment through
forming and retracting processes from the cell body, and are often present at sites where
antigen exposure is more intense. These sites include those at the body surface and
internal mucosae [135]. Immature DCs express MHC molecules, low levels of
costimulatory molecules, and chemokine receptors. In the presence of pathogens and
inflammation, immature DCs become activated and mature. Once mature, DCs increase
expression of MHC molecules and chemokine receptors and have an increased ability to
secrete cytokines and chemokines [136]. Up-regulation of chemokine receptors directs
mature DC migration to lymphoid organs where they drive various effector T cell
responses. Importantly, in absence of pathogenic and inflammatory signals, DCs promote
tolerance through inhibition of T cell reactions, specifically through clonal deletion of
inflammatory T cells and expansion of Tregs [135, 136].
Like macrophages, DCs are very heterogeneous and display plasticity. They do
not exist as one distinct population, but as an assembly of many subpopulations. Subsets
of DCs have been identified in lymphoid and non-lymphoid tissues. DCs are classified
into two main subsets: conventional myeloid derived DCs and plasmacytoid DCs.
Plasmacytoid DCs are crucial to antiviral immune responses and selectively express
TLR7 and TLR9 and large amounts of Type I IFN in both mice and humans [135]. This
dissertation discusses myeloid-derived DCs, a very heterogeneous group of cells
expressing myeloid markers, specifically CD11c, CD13, CD33, CD11b, and MHC II in
humans [137].
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Being very heterogeneous, DCs within the same species and even in different
regions of the same organ can vary in their surface expression of certain markers,
phagocytic and endocytic ability, MHC and costimulatory molecule expression, and
cytokine secretion. DCs can be stimulatory or regulatory in nature and there are many
intermediate phenotypes. Stimulatory DCs are characterized by IL-12, TNFα, IFNα, and
IL-6 cytokines and drive Th1, Th2 and Th17 responses [135]. Alternatively, regulatory
DCs are characterized by IL-10, TGFβ, indoleamine 2, 3-dioxygenase (IDO), and
arginase and drive Treg responses [137]. The functional phenotype of DCs is determined
by environmental stimuli, very similar to the determination of macrophage functional
phenotype. Additionally, there seems to be some overlap between macrophages and
myeloid DCs. In response to macrophage colony-stimulating factor (M-CSF), myeloid
DCs from blood develop a macrophage morphology [138]. Diao et al. also reported that
immunostimulatory DCs evolve into macrophage-like cells with a regulatory phenotype
during cancer [139].
DCs play a critical role at the interface of innate and adaptive immunity and
therefore it is not surprising that they are involved in the pathology of many diseases.
While stimulatory DCs are important in pathogen clearance and tumor
immunosurveillance, they have also been associated with autoimmunity. It has been
shown that the tolerogenic function of DCs is compromised in many autoimmune
diseases [137], including psoriasis [140], systemic lupus erthyematosus (SLE) [141],
allergy [142], and inflammatory bowel disease [143]. Additionally, tolerogenic DCs can
be exploited by tumors to maintain a tumor-promoting immunosuppressive environment
and also by pathogens, leading to chronic infection [137].
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Because macrophages and DCs display a wide variety of phenotypes and can be
both immunostimulatory and immunosuppressive, much interest has been generated in
the cellular mechanisms that determine their functional phenotype. Identifying and
manipulating pathways that govern macrophage and DC functional phenotype is a
promising therapeutic strategy. Specifically, through the presence or absence of various
stimuli, stimulatory macrophages and DCs may be able to be transformed into regulatory
cells and vice versa. Diseases that are characterized by macrophage and DC-driven
chronic inflammation (i.e. autoimmunity) could be treated with therapeutics that drive a
regulatory macrophage and DC functional phenotype. Alternatively, diseases that are
characterized by macrophage and DC-driven immunosuppression, like cancer, could be
treated through transforming these cells to a more immunostimulatory and anti-tumor
phenotype [120].
Our lab is interested in the mechanisms that govern DC and macrophage behavior
and through studies on fatty acid binding proteins, we became interested in AMPK as a
mediator of macrophage and DC inflammatory activity. Knowing AMPK has regulatory
roles in metabolism and inflammation, we wanted to investigate the role of AMPK in the
regulation of antigen presentation activity and TIM activity. Herein, we demonstrate that
AMPKα1 counter-regulates APC LPS and CD40-induced inflammatory activity and that
deficiency in AMPKα1 in both APC and T cells promotes Th1 and Th17 responses.
Additionally, we report that deficiency of myeloid AMPKα1 leads to reduced tumor
growth and lung metastasis and leads to higher proinflammatory signaling in TIMs.
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Figure 1. AMPK turns off ATP-consuming pathways and turns on ATP-generating
pathways. AMPK is a heterotrimeric serine/threonine kinase that is made up of a
catalytic α subunit, β scaffolding subunit, and γ regulatory subunit. AMPK senses the
cellular AMP+ADP:ATP ratio through binding of nucleotides to the γ regulatory subunit
and is allosterically activated by AMP. AMPK is activated by upstream kinases through
phosphorylation of the α subunit at Thr172. Once active, AMPK turns off ATP
consuming pathways such as those involved in the synthesis of fatty acids, sterols, and
proteins and turns on ATP generating pathways, like those involved in fatty acid
oxidation.
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Figure 2. Macrophages have a wide variety of functions. Macrophages have the ability
to perform a wide variety of activities, many in opposition to one another. Macrophages
can exhibit proinflammatory activities such as secretion of proinflammatory cytokines,
chemokines, and metabolites. Additionally, macrophages can secrete anti-inflammatory
cytokines, like IL-10 and TGFβ. Macrophages can also contribute to wound resolution
and serve as accessory cells in antigen presentation.
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Figure 3. APC present antigen to naïve T cells. APC phagocytose antigen at the sites
of infection, such as the skin, and then travel to lymphoid organs, where they display
peptide to naïve T cells and stimulate them to become effector T cells.
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CHAPTER 2
AMPKα1 DEFICIENCY AMPLIFIES PROINFLAMMATORY MYELOID APC
ACTIVITY AND CD40 SIGNALING

INTRODUCTION

APC are crucial to the development of specific immune responses that are
appropriate to different types of pathogens. It is well-reported that APC direct the
generation of inflammatory and tolerogenic immune responses. APC traffic through
peripheral tissues, sampling antigens from their microenvironment [135]. In the steady
state, much of the antigen sampled by APC is from apoptotic tissue cells during turnover
and is critical in the maintenance of self-tolerance and does not activate APC or induce
inflammation [144-146]. During infection, however, APC increase their MHC and
costimulatory molecule expression and migrate from the periphery to secondary
lymphoid organs where they display pathogenic antigens to naïve T cells and drive
effector T cell responses (Fig. 3) [135]. Migration of APC from peripheral tissues to
secondary lymphoid organs is initiated through changes in chemokine receptor and
adhesion molecule expression on the APC [147].
Through presentation of antigen to naïve T cells, APC signal important
information. Through pathogen-derived antigenic peptides bound to MHC, APC trigger
the T-cell receptor and confer the molecular identity of the pathogen. Through CD80 and
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CD86, APC provide a costimulatory second signal and indicate the pathogenic nature of
the antigen. Both the antigen-specific signal and costimulatory signals must be present to
activate antigen specific naïve T cells into effector and memory cells [148]. Additionally,
APC confer a “third signal” that contributes to the polarization of the T cell response.
APC are capable of driving a wide variety of T cell responses. Those of CD4+ T helper
(Th) are particularly varied and generally characterized by the cytokines they produce.
CD4+ Th subsets include Th1, Th2, Th17, and Treg. The type of T cell response
generated is dependent on a number of factors including the presence of pathogen
associated molecular patterns and cytokines in the microenvironment, level of
costimulation, and interactions with other immune cells [149-152]. When intracellular
pathogens (i.e. bacteria, viruses, fungi) are present, APC produce IL-12 and type I IFN
and drive CD4+ T cells to differentiate into Th1 cells that secrete IFNγ (Fig. 4).
Alternatively, the presence of extracellular pathogens such as helminths induces APC to
drive Th2 responses characterized by secretion of IL-4, IL-5, and IL-13. Th17 responses
are driven in the presence of IL-1β, IL-6, IL-23, and TGFβ and are characterized by
RORγT, IL-17, IL-21, and IL-23 production. Naïve CD4+ T cells are polarized to a Treg
phenotype when TGFβ and retinoic acid are present and result in the production of IL-10
and TGFβ [153]. Traditionally, Th subsets have been viewed as terminally differentiated
cells with a defined phenotype, but in recent years it has become apparent that some Th
subsets can display plasticity and phenotypic flexibility [154]. Specifically, Th17 and
Treg subsets display phenotypic flexibility, while Th1 and Th2 subsets change their
functional phenotype much less readily [155].
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CD40 is a transmembrane glycoprotein surface receptor and a member of the
tumor necrosis factor receptor (TNFR) family that is very important in antigen
presentation. CD40 is expressed constitutively on both DCs and macrophages and is also
expressed on monocytes, B cells, and endothelial cells [94, 156]. Binding of CD40 by its
counter-receptor, CD154 (also known as TRAP, T-BAM, CD40 Ligand, or CD40L), has
been shown to induce changes in DC that make them more effective APC, including
increased expression of MHC II as well as costimulatory molecules CD80 and CD86
[157]. CD40 ligation has also been shown to condition DCs for effective cytotoxic T
lymphocyte induction [158-160]. Additionally, CD40 signaling in DCs and macrophages
has been shown to induce production of proinflammatory cytokines and chemokines [94,
156, 157]. CD154 is expressed by activated CD4+ T cells, on many other cell types, and
in soluble form and the CD40:CD154 interaction mediates both APC and T cell
responses (Fig. 4) [94, 156].
Given the reports by our lab and others demonstrating that AMPK is an important
regulator of macrophage [106-109], DC [96], and T cell inflammatory responses [113116], we investigated the role of AMPKα1 in antigen presentation. Herein, we utilized
AMPKα1 knockout mice to analyze the role of AMPKα1 in APC function and T cellAPC interactions, including the unexplored role of AMPKα1 in CD40 signaling. Herein,
we demonstrate that AMPKα1 polarizes APC to an anti-inflammatory phenotype and
attenuates LPS and CD40-induced proinflammatory activity. Additionally, deficiency of
AMPKα1 in both APC and T cells results in enhanced capacity for production of
proinflammatory T cell responses.
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MATERIALS AND METHODS

Mice. Mice deficient for AMPKα1 were generated as described previously [161]
and provided by Dr. Leona Rubin, University of Missouri, with permission of Dr. Benoit
Viollet. AMPKα1-deficient and wild-type littermates are bred and maintained in the
University of Louisville’s Research Resources Facility. All animal care and experimental
procedures were approved by the University of Louisville’s Institutional Animal Care
and Use Committee.
Reagents. LPS (Escherichia coli serotype O111:B4) was purchased from SigmaAldrich. CD40 was activated with FLAG-tagged multimeric CD154 (MegaCD40L™)
purchased from Enzo Life Sciences. CD3 was activated with plate-bound LEAF™ antiCD3 antibody (clone 17A2) (Biolegend). Western blot detection of specific proteins used
the following primary Abs: anti-phospho-AMPKα (Thr172), anti-AMPKα, anti-phosphoERK1/2 (Thr202/Tyr204), anti-ERK1/2, anti-phospho-NF-κB p65 (Ser536), anti-NF-κB
p65, anti-phospho-p38 MAPK (Thr180/Tyr182), anti-p38 MAPK, anti-phospho-GSK3β
(Ser9), anti-GSK3β, anti-phospho-CREB (Ser133), anti-CREB, anti-phospho-Akt
(Ser473), anti-Akt (Cell Signaling Technology), anti-β-actin, and HRP-conjugated
secondary Ab (Jackson ImmunoResearch Laboratories).
ELISA. Murine bone marrow-derived DCS and macrophages were generated as
described previously [162]. Following stimulation in 96 well plates, supernatants were
collected and assayed by ELISA for TNFα, IL-6, IL-10, IFNγ (BD Biosciences), and IL-
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17 (R&D Systems) according to the manufacturer’s instructions. Analysis was performed
using an E-max precision micro plate reader (Molecular Devices).
Ag Presentation Assays. Murine bone marrow-derived DCs and macrophages
were plated (105 cells/well in 100 µL medium) with 100 µg/mL OVA peptide (Sigma
Aldrich) for 4 h. T cells isolated from spleens of OT-II mice (The Jackson Laboratory)
using CD4 (L3T4) Microbeads (Miltenyi Biotec) were then added to culture.
Supernatants were collected after 48 h and analyzed via ELISA.
Myelin oligodendrocyte glycoprotein peptide, MOG35–55, corresponding to the
sequence MEVGWYRSPFSRVVHLYRNGK was purchased from Bio-Synthesis. Mice
were injected in the flank with 100 µl of an emulsion containing 150 µg of MOG35–55 in
CFA (Sigma-Aldrich) supplemented with 500 ng of Mycobacterium tuberculosis H37Ra
(Difco Laboratories). Fourteen days later, T cells were isolated from the spleens of
immunized mice using Pan T Cell Isolation Kit II (Miltenyi Biotec). 2.5 x 105 T cells
were added to murine bone marrow DCs and macrophages that had been pulsed with 50
µg/mL MOG35–55 peptide for 1 h. Supernatants were collected and assayed by ELISA at
48 h.
Flow cytometry. Single cell suspensions of bone marrow-derived DCs and
macrophages were stained with fluorescently conjugated antibodies against murine
CD11b, CD11c, CD80, CD86, CD40, and MHC II I-Ab (all from BD Biosciences) for 30
min at 4°C, washed, and analyzed using a FACSCalibur flow cytometer and FlowJo
software (Tree Star). CD4+ T cells were isolated from spleens of wild-type mice using
CD4 (L3T4) Microbeads (Miltenyi Biotec) and were stained with fluorescently
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conjugated antibodies against murine CD4 and CD154 (both from BD Biosciences) and
analyzed using the same method.
Phagocytosis Assay. Murine bone marrow-derived DCs and macrophages were
cultured for 24 h with IgG FITC-conjugated latex beads (Cayman Chemical). Cells were
collected, stained with fluorescently conjugated antibodies against CD11c or CD11b
(both from BD Biosciences) for 30 min at 4°C, washed, and analyzed using a
FACSCalibur flow cytometer and FlowJo software (Tree Star).
Western blot analysis. Murine bone marrow-derived DCs and macrophages, and
splenic CD4+ T cells were lysed in buffer containing 125 mM Tris (pH 6.8), 2% SDS,
20% glycerol, 200 uM PMSF, protease inhibitor mixture (Promega), and phosphatase
inhibitor mixture (ThermoFisher Scientific). Total protein content of the samples was
assessed by BCA protein assay (ThermoFisher Scientific). Equal amounts of protein were
separated on 10% Criterion gels (Bio-Rad) by SDS-PAGE. Proteins were transferred to
nitrocellulose membranes using the Trans-blot Turbo Transfer System (Bio-Rad). Abbound proteins were detected using an ECL Western blotting analysis system (GE
Healthcare), and the membranes were exposed to UltraCruz 5x7 Autoradiography Film
(Santa Cruz Biotechnology) Densitometric analysis was performed using UN-SCAN-IT
gel analysis software (Silk Scientific).
Statistical Analysis. Statistical significance between groups was evaluated by
two way analysis of variance (ANOVA) followed by Bonferroni multiple comparison test
using Graphpad Prism software (Graphpad), and a level of p < 0.05 was considered
statistically significant.
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RESULTS

AMPKα1 activity counter-regulates APC inflammatory activity
The influence of AMPKα1 on APC inflammatory activity was evaluated using
bone marrow-derived DCs and macrophages generated from AMPKα1-deficient mice.
Cytokine production of AMPKα1-deficient bone marrow-derived DCs and macrophages
in response to LPS stimulation was measured by ELISA. AMPKα1-deficient APC
showed increased LPS-induced production of the proinflammatory cytokines IL-6 (Fig. 5
A, D) and TNFα (Fig. 5 B, E). Alternatively, decreased production of the antiinflammatory cytokine IL-10 was displayed by AMPKα1-deficient APC stimulated with
LPS (Fig. 5 C, F). The results of these experiments reveal that AMPKα1 counterregulates LPS-induced inflammatory cytokine production in primary macrophages and
DCs and support our previous work that utilized macrophage cell lines transfected with
DN and CA forms of AMPKα1 [106].

AMPKα1-deficient APC promote proinflammatory Th cell responses
To determine the influence of AMPKα1 on T cell-APC interactions, bone
marrow-derived DCs and macrophages generated from AMPKα1 knockout mice were
pulsed with OVA and cocultured with OT-II T cells. Cell culture supernatants were
assayed for cytokine content. AMPKα1-deficient APC induced significantly higher levels

32

of T cell production of IFNγ (Fig. 6 A, C) and IL-17 (Fig. 6 B, D) than wild-type APC,
demonstrating that absence of AMPKα1 in APC leads to a promotion of Th1 and Th17
responses.
We also evaluated APC-T cell interactions using T cells isolated from mice
immunized with MOG35–55 peptide. We verified that bone marrow-derived DCs and
macrophages, along with CD4+ splenic T cells from AMPKα1-deficient mice did not
express AMPK (Fig. 7). AMPKα1-deficient and AMPKα1+/+ APC were pulsed with
MOG35–55 peptide and co-cultured with splenic CD4+ T cells harvested from
AMPKα1+/+ and AMPKα1-/- mice that had been immunized with MOG35–55 14 d earlier.
AMPKα1-deficient APC induced significantly higher levels of IFNγ (Fig. 8 A, C) and IL17 (Fig. 9 A, C) secretion than AMPKα1+/+ APC.
Assays utilizing AMPKα1-deficient T cells provided evidence for the role of
AMPKα1 in the regulation of effector T cell responses. In assays with AMPKα1+/+
APC, T cells isolated from AMPKα1-/- mice led to increased production of IFNγ (Fig. 8
B, D) and IL-17 (Fig. 9 B, D). AMPKα1-deficiency in both cell types may promote Th1
and Th17 responses. When both APC and T cells were deficient in AMPKα1 the most
profound influence on production of IFNγ (Fig. 8 B, D) and IL-17 (Fig. 9 B, D) was
observed. T cells were isolated from total body AMPKα1-/- mice, and it is important to
consider the effect of T cell priming by AMPKα1-/- APCs in immunized mice before
they were isolated and used in our recall assay. This is addressed further in the Chapter 1
discussion. Additionally, we observed no difference in CD154 expression of AMPKα1deficient T cells compared to wild-type (Fig. 10).
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APC deficiency of AMPKα1 leads to increased expression of CD80 and CD86
To further explore the role of AMPKα1 in antigen presentation, the impact of
AMPKα1-deficiency on expression of antigen presentation machinery was evaluated.
LPS-stimulated AMPKα1-deficient DCs had significantly higher expression of
costimulatory molecules CD80 (Fig. 11 A-E) and CD86 (Fig. 12 A-E) compared to DCs
generated from control mice. AMPKα1-deficiency in LPS-stimulated macrophages
resulted in similar increases of CD80 (Fig. 11 A-E) and CD86 (Fig. 12 A-E), but did not
reach statistical significance. We did not see a significant difference in CD40 (Fig. 13) or
MHC II (Fig. 14) expression on AMPKα1-deficient bone marrow-derived DCs or
macrophages compared to those generated from control mice, nor did we see differences
in phagocytosis of latex beads (Fig. 15).

AMPKα1 regulates APC response to CD154 stimulation
The CD40:CD154 interaction is critical to productive APC-T cell interactions [94,
156]. With the demonstration that AMPKα1 influences antigen presentation and the
development of effector T cell responses, we investigated the response of myeloid APC
to CD154 stimulation. AMPKα1-deficient bone marrow-derived DCs and macrophages
were generated and evaluated for their cytokine production in response to stimulation
with a soluble, multimeric CD154. AMPKα1-deficient APC displayed increased
production of the proinflammatory cytokine IL-6 in response to CD154 stimulation (Fig.
16 A, C) and alternatively, decreased production of the anti-inflammatory cytokine IL-10
(Fig. 16 B, D). In contrast to previous observations by our laboratory and others that
proinflammatory stimuli result in decreased phosphorylation of AMPKα1 [96, 106, 107,
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163], stimulation of macrophages and DCs with CD154 at a concentration that effectively
induced a proinflammatory response (1.0 µg/mL) had no effect on phosphorylation of
AMPKα1 (Fig. 17).
We considered a number of downstream targets of AMPK as possible mediators
of the anti-inflammatory activity we observed. CD154-mediated TRAF signaling
activates the NF-κB and MAPK pathways, including p38 and ERK1/2 kinases [109, 164168]. We evaluated CD154-induced NF-κB activation through phosphorylation of p65.
As shown in Fig. 18A, CD154 induced p65 phosphorylation in AMPKα1-deficient DCs
to a much greater degree than in DCs generated from wild-type mice. Phosphorylation of
the MAPKs ERK1/2 and p38, which have been implicated in the production of
proinflammatory cytokines in response to CD40 activation [109, 166, 168], was also
evaluated. AMPKα1-deficient DCs showed much higher phosphorylation of ERK1/2 and
p38 in response to CD154 stimulation (Fig. 18 B,C)
AMPKα1 is known as a modulator of signaling events downstream of the PI3KAkt pathway [169] and in previous studies of macrophage function we found that
deficiency of AMPKα1 resulted in decreased Akt activity in response to LPS-stimulation
[106]. In the unphosphorylated state GSK3β is active and prevents IL-10 expression via
its inactivation of the transcription factor CREB. Akt can phosphorylate and inactivate
GSK3β (Ser9) such that it can no longer prevent CREB-dependent IL-10 production
[170, 171]. We evaluated phosphorylation of Akt, CREB, and GSK3β in AMPKα1deficient DCs. As shown in Fig. 19 A-C, DCs lacking AMPKα1 expression displayed
decreased phosphorylation of Akt, CREB, and GSK3β when stimulated with CD154 as
compared to DCs generated from wild-type mice.
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Figure 4. The CD40:CD154 interaction induces proinflammatory activity in
macrophages and T cells. Binding of CD40, expressed on macrophages, to its counterreceptor, CD154, on T cells results in macrophage production of proinflammatory
proteins and cytokines, such as IL-12, IL-6, and monocyte chemoattractant protein
(MCP) -1. Production of IL-12 results in the development of Th1 effector T cells.
Additionally, the CD40:CD154 engagement results in T cell IFNγ production, which
further influences macrophage activity.
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Figure 5. AMPKα1 modulates the inflammatory response of DCs and macrophages.
Bone marrow-derived DCs (A-C) and macrophages (D-F) were generated from
AMPKα1-/- and AMPKα1+/+ mice and stimulated with LPS at the concentrations shown
for 18 h or left unstimulated. IL-6, TNFα, and IL-10 levels were detected by ELISA. Data
are shown as mean ± SEM and are combined results of three independent experiments (*,
p < 0.05; **, p < 0.01).
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Figure 6. Ag presentation by AMPKα1-/- DCs and macrophages promotes
proinflammatory T cell responses. AMPKα1+/+ and AMPKα1-/- bone marrow-derived
DCs (A-B) and macrophages (C-D) were pulsed with OVA and coincubated with OT-II
CD4+ T cells for 18 h. IFNγ and IL-17 levels were detected by ELISA. Data are shown as
mean ± SEM and are combined results of three independent experiments (**, p < 0.01).
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Figure 7. AMPKα1-/- macrophages, DCs, and T cells do not express AMPKα. Bone
marrow-derived macrophages and DCs were generated from AMPKα1+/+ and AMPKα1/- mice. T cells were isolated from spleens of AMPKα1+/+ and AMPKα1-/- mice. After
cell lysis, Western blot was performed with Abs against AMPKα and β-actin.
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Figure 8. AMPKα1 deficiency in both APC and T cells leads to Th1 responses. Bone
marrow-derived DCs and macrophages were generated from AMPKα1-deficient and
AMPKα1+/+ mice. DCs (A-B) and macrophages (C-D) were pulsed with MOG35–55
before coculture with T cells from MOG35–55-immunized AMPKα1+/+ (A, C) or
AMPKα1-/- (B, D) mice. Levels of IFNγ were detected by ELISA. Data shown are mean
± SD and are representative of three independent experiments with similar results (**, p
< 0.01).
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Figure 9. AMPKα1 deficiency in both APC and T cells leads to Th17 responses.
Bone marrow-derived DCs and macrophages were generated from AMPKα1-deficient
and AMPKα1+/+ mice. DCs (A-B) and macrophages (C-D) were pulsed with MOG35–55
before coculture with T cells from MOG35–55-immunized AMPKα1+/+ (A, C) or
AMPKα1-/- (B, D) mice. Levels of IL-17 were detected by ELISA. Data shown are
mean ± SD and are representative of three independent experiments with similar results
(*, p < 0.05; **, p < 0.01).
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Figure 10. AMPKα1-deficient T cells do not display altered CD154 expression.
Surface expression of CD154 on AMPKα1+/+ and AMPKα1-/- splenic T cells was
analyzed via flow cytometry. CD154 expression of unstimulated cells (A-B) and cells
stimulated with plate-bound anti-CD3 antibody (2.5 µg/mL) for 18 h (C-D) was
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evaluated. Histograms show fluorescence of CD154 expression (black line) of CD4+ T
cells and unstained cells (solid grey peak). Mean fluorescence intensity (MFI) of
populations in brackets is stated numerically. Data shown in A-D are representative of
three independent experiments with similar results. Bar graphs (E) describe fold change
in MFI of CD154 compared to unstimulated wild-type cells and values are mean ± SEM
and are the combined results of three independent experiments.
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Figure 11. AMPKα1-deficient APC have increased expression of CD80. Surface
expression of CD80 on AMPKα1+/+ and AMPKα1-/- bone marrow-derived DCs and
macrophages was analyzed via flow cytometry. Costimulatory molecule expression of
unstimulated cells (A, B) and cells stimulated with LPS (100 ng/mL) for 18 h (C, D) was
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evaluated. Histograms show fluorescence of CD80 expression (black line) of CD11c+
(for DCs) or CD11b+ (for macrophages) cells and unstained cells (solid grey peak). Mean
fluorescence intensity (MFI) of populations in brackets is stated numerically. Data shown
in A-D are representative of three independent experiments with similar results. Bar
graphs (E) describe fold change in MFI of CD80 compared to unstimulated wild-type
cells and values are mean ± SEM and are the combined results of three independent
experiments (**, p < 0.01).
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Figure 12. AMPKα1-deficient APC have increased expression of CD86. Surface
expression of CD86 on AMPKα1+/+ and AMPKα1-/- bone marrow-derived DCs and
macrophages was analyzed via flow cytometry. CD86 expression of unstimulated cells
(A, B) and cells stimulated with LPS (100 ng/mL) for 18 h (C, D) was evaluated.
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Histograms show fluorescence of costimulatory molecule expression (black line) of
CD11c+ (for DCs) or CD11b+ (for macrophages) cells and unstained cells (solid grey
peak). Mean fluorescence intensity (MFI) of populations in brackets is stated
numerically. Data shown in A-D are representative of three independent experiments with
similar results. Bar graphs (E) describe fold change in MFI of CD86 compared to
unstimulated wild-type cells and values are mean ± SEM and are the combined results of
three independent experiments (*, p < 0.05).
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Figure 13. AMPKα1-deficiency does not alter APC CD40 expression. Surface
expression of CD40 on AMPKα1+/+ and AMPKα1-/- bone marrow-derived DCs and
macrophages was analyzed via flow cytometry. CD40 expression of unstimulated cells
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(A-B) and cells stimulated with LPS (100 ng/mL) for 18 h (C-D) was evaluated.
Histograms show fluorescence of CD40 expression (black line) of CD11c+ (for DCs) or
CD11b+ (for macrophages) cells and unstained cells (solid grey peak). Mean
fluorescence intensity (MFI) of populations in brackets is stated numerically. Data shown
in A-D are representative of three independent experiments with similar results. Bar
graphs (E) describe fold change in MFI of CD40 compared to unstimulated wild-type
cells and values are mean ± SEM and are the combined results of three independent
experiments.

49

Figure 14. AMPKα1-deficient APC do not have altered expression of MHC II.
Surface expression of MHC II on AMPKα1+/+ and AMPKα1-/- bone marrow-derived
DCs and macrophages was analyzed via flow cytometry. MHC II expression of
unstimulated cells (A-B) and cells stimulated with LPS (100 ng/mL) for 18 h (C-D) was
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evaluated. Histograms show fluorescence of MHC II expression (black line) of CD11c+
(for DCs) or CD11b+ (for macrophages) cells and unstained cells (solid grey peak). Mean
fluorescence intensity (MFI) of populations in brackets is stated numerically. Data shown
in A-D are representative of three independent experiments with similar results. Bar
graphs (E) describe fold change in MFI of MHC II compared to unstimulated wild-type
cells and values are mean ± SEM and are the combined results of three independent
experiments.
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Figure 15. AMPKα1-deficiency does not alter APC phagocytosis of latex beads.
AMPKα1+/+ and AMPKα1-/- bone marrow-derived DC and macrophage phagocytosis
of latex beads was analyzed via flow cytometry. FITC+ latex bead fluorescence of
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unstimulated cells (A-B) and cells stimulated with LPS (100 ng/mL) for 18 h (C-D) was
evaluated. Histograms show fluorescence of FITC expression (black line) of CD11c+ (for
DCs) or CD11b+ (for macrophages) cells and unstained cells (solid grey peak). Mean
fluorescence intensity (MFI) of populations in brackets is stated numerically. Data shown
in A-D are representative of three independent experiments with similar results. Bar
graphs (E) describe fold change in MFI of FITC compared to unstimulated wild-type
cells and values are mean ± SEM and are the combined results of three independent
experiments.
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Figure 16. AMPKα1 regulates the inflammatory cytokine response of APC to
CD154 stimulation. Bone marrow-derived DCs (A-B) and macrophages (C-D) were
generated from AMPKα1-/- and AMPKα1+/+ mice and stimulated with CD154 at the
concentrations shown for 18 h or left unstimulated. IL-6 and IL-10 cytokine levels were
detected by ELISA. Data shown are mean ± SEM and are the combined results of three
independent experiments (*, p < 0.05; **, p < 0.01).
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Figure 17. CD154 stimulation of DCs and macrophages has no effect on
phosphorylation of AMPKα. Bone marrow-derived DCs (A) and macrophages (B)
generated from AMPKα1+/+ mice were stimulated with 1.0 µg/mL CD40L for the
timepoints indicated. After cell lysis, Western blot was performed using Abs against pAMPK (Thr172) and total AMPK. Data shown are representative of four independent
experiments with similar results.
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Figure 18. AMPKα1 expression modulates CD40-induced NF-κB, ERK1/2, and p38
signaling in DCs. Bone marrow-derived DCs were generated from AMPKα1-/- and
AMPKα1+/+ mice and stimulated with 1.0 µg/mL CD154 for the time points indicated.
After cell lysis, Western blot was performed using Abs against p-NF-κB p65 (Ser536)
and total NF-κB p65 (A), p-ERK1/2 (Thr202/Tyr204) and total ERK1/2 (B), and p-p38
MAPK (Thr180/Tyr182) and p38 MAPK (C). Bands were analyzed by densitometry and
displayed as bar histograms. Data shown are representative of three (B, C) and four (A)
independent experiments with similar results.
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Figure 19. AMPKα1 expression modulates CD40-induced Akt- CREB- GSK3β
signaling in DCs. Bone marrow-derived DCs were generated from AMPKα1-/- and
AMPKα1+/+ mice and stimulated with 1.0 µg/mL CD154 for the time points indicated.
After cell lysis, Western blot was performed using Abs against p-Akt (Ser473) and total
Akt (A), p-CREB (Ser133) and total CREB (B), and p-GSK3β (Ser9) and total GSK3β
(C). Bands were analyzed by densitometry and displayed as bar histograms. Data shown
are representative of three (A, C) and four (B) independent experiments with similar
results.
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DISCUSSION

AMPK has been recognized recently as a counter-regulator of inflammatory
pathways including those induced by TLR and IFNγ stimulation [96, 106, 163] and fatty
acids [107, 108]. Our previous work utilizing macrophage cell lines transfected with CA
and DN forms of AMPKα1, as well as AMPKα1 siRNA knock down, revealed
AMPKα1’s role as a negative regulator of TLR-mediated inflammatory activity [106]. In
this report, use of primary myeloid APC generated from AMPKα1-deficient mice
confirms the function of AMPKα1 in the suppression of TLR-mediated induction of
proinflammatory cytokine production and the enhancement of anti-inflammatory IL-10
production (Fig. 5) and establishes AMPKα1 as a regulator of APC activity and CD40
signal transduction (Figs. 18-19). These data suggest that the influence of AMPK
activators on development of autoimmune disease in mice [43, 98] could be largely due
to AMPKα1’s regulatory role in the outcome of CD154:CD40 interactions during initial
APC events as well as during T cell activation of myeloid cells at the sites of
inflammation.
We investigated a number of downstream effectors of AMPKα1 to determine the
mechanism by which AMPKα1 exerts its anti-inflammatory influence on CD40 signaling
including the Akt-GSK3β pathway known to be suppressive of TLR-mediated
inflammatory signaling [170, 171]. Previous reports on the association of AMPK and Akt
activation have shown mixed results, with some suggesting that AMPK activation is
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positively correlated with Akt activation and others reporting an association of AMPK
activity with decreased Akt activity (reviewed in Ref. [169]). We have previously shown
a positive association of AMPKα1 and Akt in macrophages stimulated with LPS [106].
Likewise, in the present study, AMPKα1-deficient DCs responded to CD154 stimulation
with decreased Akt activity, enhanced GSK3β activity, and decreased CREB activation
(Fig. 19 D-F).
Akt must be phosphorylated at two sites to become active: Thr308 by
phosphoinositide-dependent kinase I (PDK1) [172, 173] and Ser473 by the mTOR
complex (mTORC) 2 [174]. When cellular energy becomes low, AMPK phosphorylates
and activates TSC2, an inhibitor of mTOR [67] and alternatively Akt can phosphorylate
and inactivate TSC2, thereby activating mTORC1 [175, 176]. mTORC1 regulates mRNA
translation in part through phosphorylation and activation of S6K1 [177], which has been
shown to phosphorylate and inactivate GSK3β [178]. This fits with our data showing that
decreased AMPK activity is associated with decreased Akt phosphorylation (Ser473) and
decreased phosphorylation (Ser9) of GSK3β in CD154-stimulated DCs (Fig. 19 A, C).
GSK3β is a negative regulator of the transcription factor CREB, and
phosphorylation and inactivation of GSK3β enhances CREB activity [170, 171]. It is
thought that inhibition of GSK3β allows CREB to compete for the nuclear coactivator
protein CREB-binding protein, which is required for NF-κB activity. This results in
reduced NF-κB activation and enhanced expression of CREB-activated IL-10 synthesis
[171]. Accordingly, we observe decreased CREB phosphorylation (Fig. 19B) and
increased phosphorylation of p-65 NF-κB (Fig. 18A) in AMPKα1-deficient DCs
stimulated with CD154. AMPKα1-deficient DCs and macrophages also have increased
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NF-κB production of proinflammatory cytokines and decreased synthesis of IL-10 in
response to TLR- and CD154-stimulation (Fig. 5 and 16).
Our studies herein indicate that deficiency of AMPK has no effect on the
phagocytosis of latex beads (Fig. 16). This result is in contrast to a previous report
showing activation of AMPK via AICAR and metformin increases macrophage
phagocytosis of apoptotic cells and bacteria [179]. As previously described, AICAR and
metformin have AMPK-independent effects and thus it is possible the observed increase
in phagocytic activity was independent of AMPK.
We also found that absence of AMPK in APC led to increased expression of
CD80 and CD86 (Fig. 11-12). It has been previously reported that treatment of DCs with
AICAR and LPS results in an AMPKα1-independent decrease in expression of CD80,
CD86, CD40, and MHC II I-Ab [43]. Although AICAR has many AMPKα1-independent
effects, our results demonstrate that AMPKα1 activity is involved in the regulation of
CD80 and CD86 expression (Fig. 11-12). The increased presence of CD80 and CD86
costimulatory molecules in AMPKα1-deficient APC is associated with a robust induction
of Th1 and Th17 responses (Fig. 6, 8-9).
In addition to AMPKα1 expression by APC, we demonstrate a role for T cellexpressed AMPKα1 in the development of Th immune responses (Fig. 8-9). Previous
reports on the role of AMPK in CD4+ T cells show mixed results. One study implicated
AMPKα1 in the regulation of inflammatory cytokine production by CD8+ T cells, but not
CD4+ T cells [116]. A requirement for AMPK activity for Treg function has been
reported [37]. It has also been shown that in vivo AICAR treatment in a murine model of
EAU resulted in decreased CD4+ Th1 and Th17 T cell responses [43]. Our results fit with
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the latter studies, wherein absence of AMPKα1 in CD4+ T cells leads to development of
proinflammatory T cell responses (Figs. 11-12).
It is very important to note that in our studies of T-cell expressed AMPKα1, T
cells were isolated from MOG35-55-immunized total body AMPKα1-/- mice and
restimulated with AMPKα1+/+ and AMPKα1-/- bone marrow-derived APCs pulsed with
MOG35-55 peptide. Because the T cells were taken from total body AMPKα1-/- knockout
mice, they may have been primed by AMPKα1-/- DCs before we isolated them from the
spleen and utilized them in our recall assay. It is therefore difficult to determine from this
experiment the extent to which T cell AMPKα1-deficiency led to higher production of
proinflammatory cytokines compared to the potential effect of priming by an AMPKα1deficient APC.
Excessive proinflammatory T cell responses are associated with autoimmune disease,
including rheumatoid arthritis, and therapeutic strategies include targeting factors that can
dampen these T cell responses. Our results indicate that AMPKα1 is one such potential
target, as AMPKα1 expression in APC leads to reduced IFNγ and IL-17 T cell production
in antigen presentation assays (Figs. 6, 8-9). Additionally, there are several therapeutic
strategies that may benefit from inhibition of AMPK and activation of a proinflammatory
DC response. Tolerogenic DCs are an obstacle to the success of DC vaccine
immunotherapy and inhibition of AMPK may increase DC proinflammatory activity and
result in a more effective vaccine. Although this has not yet been tested to our
knowledge, AMPK inhibition in myeloid cells may lead to a greater immune response
against pathogenic microbes, parasites, etc. Additionally, an immunosuppressive
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environment perpetuates cancer pathology and inhibition of AMPKα1 to activate a
proinflammatory immune response may be a valuable anti-cancer therapeutic strategy.
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CHAPTER 3
MACROPHAGE-EXPRESSED AMPKα1 REGULATES TUMOR GROWTH

INTRODUCTION

More men and women die from cancer of the lung than that of any other tissue
[180]. Nearly 80% of lung malignancies are non-small cell lung cancers (NSCLC), which
have a grim prognosis. Only 15% of patients survive five years beyond diagnosis with
NSCLC. It is widely accepted that chronic cigarette smoke is the largest contributor to
lung cancer development, however it is not the only factor involved, as many chronic
smokers do not develop cancer and, alternatively, lung cancer arises in nonsmokers,
although rarely [181]. Being such a common and deadly disease, there is much interest in
the development of new therapeutics for lung cancer.
Inflammatory processes have been shown to be highly involved in cancer
development and progression. Chronic inflammation has been identified as a significant
player in the development of many cancers and treatment with anti-inflammatory drugs
has been shown to reduce cancer risk [182]. In conditions of chronic inflammation, it is
evident that persistent recruitment of immune cells leads to higher production of reactive
nitrogen and oxygen species, creates a mutagenic environment, and induces
transformation of proximal epithelial cells. Additionally, chronic inflammation creates an
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environment rich in growth factors and cytokines that may induce premalignant cell
proliferation and survival [183]. Many inflammatory pathways are suspected to
contribute to lung cancer development. NF-κB signaling, in particular, is thought to play
a major role [184]. There is some degree of immune cell infiltration in all tumors, with
some tumors displaying minimal infiltration and others much heavier [185]. Although
some reports indicate that infiltrating immune cells can be involved in eradication of
tumors, it is apparent that many infiltrating cells are supportive of tumor growth and
metastasis [186]. TIMs, in particular, have been shown to be involved in tumorsupporting immune activities.

TUMOR-INFILTRATING MACROPHAGES
Monocytes are actively recruited to tumors from the bloodstream through the
expression of various chemokines by malignant and stromal cells in tumors [186]. These
include macrophage colony stimulating factor (M-CSF), MCP-1, CCL2, CCL3, CCL4,
CCL5, CCL8, and VEGF [187]. VEGF is a major chemoattractant for monocytes and
macrophages, and it is evident that more macrophages are found in VEGF-positive
human breast carcinomas than those negative for VEGF [188, 189]. CXCL12 has also
been shown to attract monocytes and macrophages to tumors, and has been linked to their
recruitment to hypoxic areas of tumors [190].
The accumulation of macrophages and monocytes in tumors has been longassociated with poor prognosis in many cancers. Over 80% of studies published correlate
a high density of TIMs with grim prognosis [191]. These include cancers of the breast,
prostate, endometrium, bladder, kidney, and esophagus, along with squamous cell
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carcinoma and follicular lymphoma [186]. Alternatively, there are some cancers where
high numbers of TIMs correlate with a favorable prognosis, including stomach,
colorectal, and melanoma [186]. It was originally thought that infiltrating immune cells
were involved in the generation of an anti-tumor response, and indeed, macrophages from
healthy or inflamed tissues display an ability to lyse malignant cells, present tumor
antigens, and produce proinflammatory cytokines stimulating anti-tumor T cell and NK
cell activities [186]. Although macrophages are capable of generating anti-tumor
immunity, those isolated from tumors both in human and animal models, do not display
these activities. Instead, TIMs display an “alternative” functional phenotype associated
with enhanced anti-inflammatory cytokine expression, promotion of angiogenesis, and
poor antigen presentation capability [192]. In response to an immunosuppressive tumor
microenvironment, TIMs are subverted by the tumor and have been shown to promote
tumor angiogenesis, invasion, metastasis, and generalized immunosuppression in the
tumor microenvironement [120, 186]. Even within the tumor, macrophages display
significant heterogeneity, and functional phenotypes are generally attributed to the
discrete microenvironments of different areas of the tumor [120].
Macrophages are recruited to hypoxic and necrotic areas of the tumor and it is
apparent that conditions there immobilize them, leading to significant accumulation of
macrophages in these regions. TIMs near blood vessels are involved in tumor cell
invasion and metastasis. TIMs produce a number of pro-angiogenic cytokines, such as
TNFα and IL-8, growth factors like VEGF and basic fibroblast growth factor (bFGF), and
enzymes including MMP-2, MMP-7, MMP-9, MMP-12, and COX-2 [193]. These
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angiogenic factors are likely responsible for the correlation observed between increased
TIM accumulation and high vascular grade of many cancers [194, 195].
It has been demonstrated that macrophages assist tumor cell migration away from
the main body of the tumor and extravasation into blood vessels [120]. The coordination
of tumor cell and macrophage activities seems to be dependent upon EGF and CSF-1
signaling, respectively, as inhibition of either pathway blocks mobilization of both cell
types [196, 197]. Macrophages induce tumor cell migration through expression of
chemoattractants like EGF. In response to triggering of the EGFR, tumor cells secrete
CSF-1, attracting macrophages and inducing them to secrete EGF [183]. An EGF/CSF-1
paracrine loop is thought to have a major role in metastasis, supported by clinical reports
indicating CSF-1 expression in tumor cells and EGF expression in macrophages are both
indicators of poor prognosis [198, 199]. Studies of human breast and bone cancer have
also indicated that CSF-1 expression is associated with increased metastasis [200].
In addition to coordination of tumor cell escape from the primary tumor,
macrophages aid in the establishment of metastases at distant sites. In a breast cancer
mouse model, systemic depletion of macrophages resulted in reduced lung metastasis
[201]. It is also evident that alveolar macrophage and endothelial cell expression of
MMP-9 and VEGF is necessary for the colonization and growth of tumor cells in the lung
[202]. Studies indicating that macrophages at metastatic sites support tumor formation are
supported by clinical evidence that high counts of macrophages in regional lymph node
metastases are associated with decreased patient survival [203].
Macrophages have also been implicated in the establishment and maintenance of
the immunosuppressive tumor microenvironment. Several reports indicate that tumor-
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derived cytokines, growth factors, proteases, and chemokines influence macrophage
phenotype and function within the tumor [204-206]. Tumor-derived factors such as IL-4,
IL-6, IL-10, and TGFβ inhibit cytotoxic activity of macrophages in the tumor [204, 207].
Several of these mediators have also been shown to reduce macrophage MHC II
expression and are thought to inhibit presentation of tumor-associated antigens to T cells,
and anti-tumor immunity [204]. TIMs display suppressed IL-12 production, a cytokine
involved in NK and T cell cytotoxic responses [208]. Hypoxia within the tumor likely
contributes to immunosuppressive macrophage activity, as it impairs the development of
immune cells from their precursors and the anti-tumor functions of any immune cells that
are formed [204, 209]. Additionally, hypoxia suppresses macrophage phagocytosis of
dead and dying cells and expression of the costimulatory molecule CD80, further
suppressing anti-tumor activities [204, 209, 210]. Generally, TIMs are strongly polarized
towards anti-inflammation by tumor-derived factors and play a large role in the
subversion of many kinds of anti-tumor immunity.
Peritumor and distal macrophages produce prostaglandin E2, TGFβ, and IL-10
[204] and are thought to spread immunosuppression from the site of the tumor and
provoke systemic immune suppression. Macrophages in various tissues display an
immunosuppressive phenotype regardless of the presence or absence of metastases [204,
211]. Although the mechanism by which the primary tumor induces immunosuppression
in distal macrophages has not been elucidated, it has been shown that tumors release
microvesicles expressing various ligands and cytokines. These microvesicles are
suspected to not only generate an immunosuppressive functional phenotype in
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macrophages, but also downregulate NK cell activity, prevent maturation of myeloid DCs
and the generation of anti-tumor T cell immune responses [212].
In addition to macrophages, immature myeloid cells called myeloid-derived
suppressor cells (MDSC) accumulate in the tumor and play an important role in
immunosuppression. In mice, MDSC are Gr1+CD11b+ and are subtyped as granulocytic
MDSC (G-MDSC) characterized by a CD11b+Gr1hiLy6G+Ly6Clow/medCD49d- phenotype
and monocytic MDSC (M-MDSC) characterized by a CD11b+Gr1midLy6GLy6ChiCD49d+ phenotype. It has been observed that tumor expansion of MDSC is mostly
restricted to G-MDSC in the majority of tumor models [213]. MDSC suppress T cell
responses through a variety of mechanisms, including production of reactive oxygen
species [213]. MDSC also promote activation and expansion of Treg [214], downregulate
macrophage IL-12 production [215], and induce antigen specific tolerance of CD8+ [216]
and possibly CD4+ [217] T cell responses .
The strong immunosuppression established through MDSC and TIMs is a major
obstacle in the development of cancer therapeutic strategies [218]. It has been shown that
macrophages from healthy and inflamed tissues can generate potent anti-tumor responses,
and remarkably, several reports have demonstrated that TIMs can be induced to display
anti-tumor cytotoxic activities [219-223]. Studies indicate that increasing the presence of
IL-12 [219, 223], induction of CD40 signaling [221, 222], and depletion of IL-10 [220]
may be effective ways of altering immunosuppressive TIMs to generate cytotoxic
activities. Reprogramming macrophages to reduce or eliminate their support for tumor
angiogenesis, invasion, and metastasis and enhance their support for anti-tumor NK and
T cell cytotoxic adaptive responses is a promising therapeutic strategy [120].
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Previous studies from our lab [106] along with those described herein (Chapter 2)
indicate that AMPKα1 is a counter-regulator of myeloid inflammatory activity. LPS and
CD40 stimulation of AMPKα1-deficient macrophages results in increased
proinflammatory cytokine production and decreased production of the anti-inflammatory
cytokine IL-10 [Figs. 5 and 16 and Ref. [106]. Additionally, it is apparent that absence of
AMPKα1 in both macrophages and DCs results in promotion of Th1 and Th17 responses
(Figs. 6, 8-9) and increased expression of costimulatory molecules CD80 and CD86
(Figs. 11-12). Having demonstrated that absence of AMPKα1 results in a
proinflammatory myeloid functional phenotype, we wanted to investigate the role of
macrophage-expressed AMPKα1 on tumor-macrophage interactions and macrophage
polarization in the tumor microenvironment. Herein, we utilize an AMPKα1 Cre-lox
transgenic mouse model to determine the effect of myeloid-expressed AMPKα1 on LLC
tumor growth and metastasis. We found that decreased AMPKα1 expression amplified
TIM proinflammatory activity and resulted in decreased tumor growth and metastasis.
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MATERIALS AND METHODS

Mice. AMPKα1flox/flox LysM-Cre+ (MacAMPKα1 KO) mice were generated
through crossing LoxP AMPKα1 mice, provided by Benoit Viollet, with LysM-Cre mice
(The Jackson Laboratory). AMPKα1flox/flox LysM-Cre+ (MacAMPKα1 KO) and
AMPKα1flox/- LysM-Cre- (WT) mice are bred and maintained at the University of
Louisville Research Resources Facility. All animal care and experimental procedures
used in this study were approved by the University of Louisville’s Institutional Animal
Care and Use Committee.
Tumor model. LLC tumor tissues were generated as previously described [224]
and provided by Dr. Chi-Ping Day at the National Cancer Institute (Bethesda, Maryland).
Tumor tissues were thawed, gently dissociated with a scalpel, and cultured in vitro to
produce a viable cell line. Tumors were then maintained by in vivo passage with limited
intermittent culture in vitro. Tumor cells (2 x 105) were injected subcutaneously into the
right flank of MacAMPKα1 KO and WT mice. Five to seven mice were used in each
group. Tumors were measured every 2-3 days with calipers at two bisecting diameters
and an approximate volume was calculated by the formula (long side x short side2) x 6/π.
Mice were sacrificed after 18 days.
To prepare single cell suspensions, resected tumors were digested using a tumor
dissociation kit (Miltenyi Biotec) and MACS tissue dissociator (Miltenyi Biotec). The
resulting cell suspensions were filtered through 70µm cell strainers (BD Biosciences) and
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washed with 5% FBS in RMPI 1640. Tumor-infiltrating CD11b+ cells were isolated by
positive selection with anti-CD11b (Mac-1) magnetic beads (Miltenyi Biotec). A purity
of >95% CD11b+ cells was confirmed by flow cytometry.
Flow Cytometric Analysis. Single cell suspensions were stained with
fluorescently conjucated antibodies against murine CD4, CD8, CD19, CD11c, CD11b,
F4/80, and NK1.1 (all from BD Biosciences) for 30 minutes at 4ºC, washed, and
analyzed using a FACSCalibur flow cytometer and FlowJo software (Tree Star Inc.). A
sample of 10,000 cells was isolated from each tumor and the number of positively stained
cells in the sample was determined and expressed as a percentage. The calculated
percentage was multiplied by the total number of tumor cells to determine the number of
positively stained cells in the tumor.
Quantitative Real-time RT-PCR analysis. mRNA was isolated from 106
purified TIMs and converted to cDNA using MACS One-Step cDNA Columns (Miltenyi
Biotec). Real-time RT-PCR was performed with a DNA-Opticon 3 Monitor (Bio-Rad)
using SYBR Green (Qiagen). IL-6, TNFα, IL-23, and MMP-12 expression was analyzed
by Quantitect Primer Assays (Qiagen). Results were normalized to β-actin. Relative
expression of RNA transcripts was quantified using the Relative Expression Software
Tool, REST.
Western blot analysis. 106 macrophages were lysed in buffer containing 125 mM
Tris (pH 6.8), 2% SDS, 20% glycerol, 200 uM PMSF, protease inhibitor mixture
(Promega), and phosphatase inhibitor mixture (ThermoFisher Scientific). Total protein
content of the samples was assessed by BCA protein assay (ThermoFisher Scientific).
Equal amounts of protein were separated on 10% Criterion gels (Bio-Rad) by SDS-
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PAGE. Proteins were transferred to nitrocellulose membranes using the Trans-blot Turbo
Transfer System (Bio-Rad). Ab-bound proteins were detected using an ECL Western
blotting analysis system (GE Healthcare), and the membranes were exposed to UltraCruz
5x7 Autoradiography Film (Santa Cruz Biotechnology). Densitometric analysis was
performed using UN-SCAN-IT gel analysis software (Silk Scientific).
Statistical Analysis. Statistical significance between groups was evaluated as
indicated by unpaired t test or two way analysis of variance (ANOVA) followed by
Bonferroni multiple comparison test using Graphpad Prism software (Graphpad, La Jolla,
CA), and a level of p < 0.05 was considered statistically significant.
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RESULTS

Deficiency of myeloid cell-expressed AMPKα1 results in decreased rate of tumor
growth and metastasis.
To determine the role of myeloid cell-expressed AMPKα1 in tumor growth, we
utilized an AMPKα1 Cre-lox transgenic mouse model. Previous studies demonstrated the
predominant expression of LysM in the myeloid lineage [225], and AMPKα1flox/flox
LysM-Cre+ (MacAMPKα1 KO) mice have myeloid-specific deficiency in AMPKα1.
MacAMPKα1 KO and WT mice were subcutaneously injected in the flank with LLC
tumor cells. Caliper measurements of tumor volume (Fig. 20) indicated that
MacAMPKα1 KO mice had reduced tumor growth compared to WT mice through 18
days post-injection. Tumors harvested at day 18 from MacAMPKα1 KO mice weighed
less than those from WT mice (Fig. 21). We also wanted to evaluate the role of myeloid
cell-expressed AMPKα1 on lung metastasis. MacAMPKα1 KO mice had a lower number
of lung metastases (Fig. 22).
As decreases in body weight can indicate muscle wasting and severe illness, we
periodically weighed mice throughout the experiment. Both MacAMPKα1 KO

73

and WT mice maintained weight throughout the course of tumor growth, indicating that
tumor burden did not result in muscle wasting (Fig. 23).

MacAMPKα1 KO mice have increased CD19+ and decreased CD8+ immune cell
infiltration of primary tumors
It has been well-established that immune cells infiltrate tumors, including
macrophages, natural killer (NK) cells, CD4+ and CD8+ T cells, B cells, and DCs. We
wanted to determine the degree of infiltration of various immune cells into primary
tumors of MacAMPKα1 KO and WT mice. We evaluated immune cell infiltration as a
percentage of a sample of 10,000 tumor cells (Fig. 24A) and the number of infiltrating
immune cells in the total tumor (Fig. 24B).
The percentage of infiltrating cells expressing CD19+, a B cell marker, was
significantly increased in tumors from MacAMPKα1 KO mice compared to WT (Fig.
24A). The number of infiltrating CD19+ B cells in the tumor was also increased in tumors
from MacAMPKα1 KO mice compared to WT, but the difference was not significant
(Fig. 24B). Additionally, the number of infiltrating CD8+ T cells was significantly
decreased in tumors from MacAMPKα1 KO mice, compared to those from WT mice
(Fig. 24B). The percentage of CD8+ T cells in tumors from MacAMPKα1 KO mice was
decreased compared to tumors from WT mice, but the difference was not significant (Fig.
24A). Expression of NK cell (Ly6G/NK1.1), CD4+ T cell, macrophage (F4/80/CD11b),
and DC (CD11c) markers of single cell suspensions from MacAMPKα1 KO primary
tumors was similar to those from WT tumors (Fig. 24), indicating that deficiency of
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AMPKα1 in myeloid cells does not impact the infiltration of these immune cell
populations in the tumor.

TIMs from MacAMPKα1 KO mice have increased expression of proinflammatory
mediators
The immunosuppressive tumor microenvironment has been associated with
increased tumor growth and invasion, and macrophages drive this pathology [120]. As
deficiency in AMPKα1 has been shown to lead to proinflammatory activity in
macrophages [106, 107, 163], we wanted to characterize TIMs in tumors of
MacAMPKα1 KO mice. We first verfied that TIMs isolated from MacAMPKα1 KO
mice had dramatically reduced expression of phosphorylated and total AMPK compared
to control mice (Fig. 25).
TIMs isolated from MacAMPKα1 KO mice had higher mRNA expression of
proinflammatory cytokines IL-6, TNFα, and IL-23 compared to WT mice (Fig. 26).
Additionally, MacAMPKα1 KO mice had significantly higher expression of MMP-12
mRNA (Fig. 26) and MMP-9 protein (Fig. 27), indicating that TIMs from MacAMPKα1
KO mice have higher expression of proinflammatory mediators.
We considered a number of downstream targets of AMPKα1 as possible
mediators of the anti-inflammatory activity we observed. As we had previously observed
an association of AMPK activity and decreased phosphorylation of p65 NF-κB (Fig. 18),
we evaluated TIM NF-κB activation through phosphorylation of p65. As shown in Fig.
28, p65 phosphorylation was significantly higher in TIMs from MacAMPKα1 KO mice
compared to those from WT mice. Additionally, TIMs from MacAMPKα1 KO mice had
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significantly decreased expression of p-Akt (Fig. 29A) and p-CREB (Fig. 29B). These
data demonstrate that TIMs isolated from MacAMPKα1 KO mice have higher
proinflammatory activity compared to those isolated from WT mice, a factor that may
contribute to the reduced tumor growth (Figs. 20-21) and lung metastasis (Fig. 22)
observed in MacAMPKα1 KO mice.
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Figure 20. MacAMPKα1 KO mice have decreased rate of LLC tumor growth.
MacAMPKα1 KO and WT mice were injected subcutaneously with LLC tumor cells (2 x
105) and growth was measured every 2-3 days for 18 days using caliper measurements.
Tumor volume was calculated using the formula (long side x short side2) x 6/π. Data are
mean ± SEM of results combined from two independent experiments, with 5-7 mice per
group in each experiment (**, p < 0.01).
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Figure 21. Tumors harvested from MacAMPKα1 KO mice weigh less than those
from WT mice. MacAMPKα1 KO and WT mice were injected subcutaneously with LLC
tumor cells (2 x 105) and tumors were harvested 18 days later and weighed. Data are
mean ± SEM of results combined from two independent experiments, with 5-7 mice per
group in each experiment (*, p < 0.05).
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Figure 22. Lungs from MacAMPKα1 KO mice have reduced lung metastases.
MacAMPKα1 KO and WT mice were injected subcutaneously in the flank with LLC
tumor cells and lung metastasis was assessed 18 days later. Lungs were perfused and
stained with Bouin’s solution to visualize metastases. Representative lungs were
photographed (A) and lung metastases were counted (B). Images in A are representative
of two separate experiments with similar results and five or more mice in each group. For
B, data are expressed as mean ± SEM of results combined from two independent
experiments, with 5-7 mice per group in each experiment (*, p < 0.05).
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Figure 23. MacAMPKα1 KO and WT mice maintain weight throughout tumor
growth and metastasis. All mice were injected subcutaneously with LLC tumor cells (2
x 105) on day 0 and the weight of each mouse was taken every 2-3 days until day 18 (A).
Average weights of each strain were calculated over time (B). Data are representative of
three separate experiments with similar results and five to seven mice in each group.
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Figure 24. MacAMPKα1 KO mice have increased CD19+ and decreased CD8+
immune cell infiltration of primary tumors. Single cell suspensions of primary tumors
isolated from MacAMPKα1 KO and WT mice were generated and expression of various
immune cell markers was evaluated via flow cytometry. The number of positively stained
cells in a sample of 10,000 tumor cells was determined and is expressed as a percentage
(A). The number of positively stained cells in the total tumor was determined and is
expressed as cell number (B). Data are expressed as mean ± SEM and are the combined
results of two independent experiments with 5-7 mice per group (*, p < 0.05).
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Figure 25. TIMs isolated from MacAMPKα1 KO mice have decreased expression of
AMPKα. TIMs were isolated from primary tumors of MacAMPKα1 KO and WT mice.
After cell lysis, Western blot was performed using Abs against p-AMPKα (Thr172), total
AMPKα, and β-actin. Data shown are representative of two experiments of five mice per
group, and each band is protein expression from one mouse.
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Figure 26. TIMs isolated from MacAMPKα1 KO mice have higher expression of
proinflammatory cytokines and MMP-12 than WT mice. TIMs were isolated from
primary tumor cell suspensions and mRNA expression was evaluated via RT-PCR and is
expressed as fold difference compared to TIMs isolated from WT mice. Data expressed
are from individual mice and are representative of two experiments with similar results
and five or mice in each group (**, p < 0.01).
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Figure 27. TIMs isolated from MacAMPKα1 KO mice have increased MMP-9
expression. TIMs were isolated from primary tumors of MacAMPKα1 KO and WT
mice. After cell lysis, Western blot was performed using Abs against MMP-9 and β-actin.
Each band is TIM protein expression from one mouse (A). Densitometric analysis was
performed and the average MMP-9 / β-actin protein expression for MacAMPKα1 and
WT TIMs was determined (B). Data shown are representative of two experiments of four
to five mice per group (*, p < 0.05).
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Figure 28. TIMs isolated from MacAMPKα1 KO mice have increased
phosphorylation of NF-κB p65. TIMs were isolated from primary tumors of
MacAMPKα1 KO and WT mice. After cell lysis, Western blot was performed using Abs
against p-NF-κB p65 (Ser536) and total NF-κB p65. Each band is TIM protein
expression from one mouse (A). Densitometric analysis was performed and the average
p-p65 / p65 / β-actin protein expression for MacAMPKα1 and WT TIMs was determined
(B). Data shown are representative of two experiments of four to five mice per group (**,
p < 0.01).
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Figure 29. TIMs isolated from MacAMPKα1 KO mice have decreased
phosphorylation of Akt and CREB. TIMs were isolated from primary tumors of
MacAMPKα1 KO and WT mice. After cell lysis, Western blot was performed using Abs
against p-Akt (Ser473) and total Akt (A), p-CREB (Ser133) and total CREB (B), and βactin. Each band is TIM protein expression from one mouse (A-B). Densitometric
analysis was performed and the average p-Akt / Akt (C) and p-CREB / CREB (D) protein
expression for MacAMPKα1 and WT TIMs was determined. Data shown are
representative of two experiments of four to five mice per group (*, p < 0.05).
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DISCUSSION

Macrophages display remarkable plasticity and can exhibit a number of functional
phenotypes [120, 226]. TIMs are often found in high number in tumors [227] and usually
indicate a poor prognosis [191]. TIMs often exhibit an anti-inflammatory, pro-tumor
phenotype that is shaped by mediators found within the tumor microenvironment and
TIMs are considered a major obstacle to the development of cancer therapeutics [120].
Despite the significant effects of macrophage polarization on tumor biology, the
molecular and transcriptional mediators that control the pro-tumor phenotype of TIMs
remain largely unknown.
Activation of AMPK has been a therapeutic strategy for the treatment of cancer
for some time. Interest in AMPK activation for tumor therapy began with the discovery
that LKB1, a known tumor suppressor, is an upstream kinase required for AMPK
activation [20]. AMPK activation for cancer therapy is supported by the observation that
diabetic patients treated with metformin have a decreased lifetime cancer risk [83].
Studies in tumor mouse models utilizing AICAR and metformin have shown an
association of AMPK activation and decreased tumor growth [81, 84, 85]. It has been
reported that AMPK activation is not beneficial in all cancers, however, including some
oncogene-driven melanomas [228] and prostate cancers [89, 90], suggesting that the role
of AMPK in cancer development is more complicated than originally thought. Very little
is known about the contribution of immune cell-expressed AMPKα1 to tumor growth and
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metastasis. Our studies herein demonstrate that AMPKα1 activity in myeloid cells
contributes to the anti-inflammatory phenotype of TIMs and is associated with increased
tumor growth. We are not aware of any other study evaluating the role of AMPKα1 in
TIM promotion of tumor growth.
Mice deficient in myeloid-expressed AMPKα1 had significantly decreased tumor
growth from days 14-18 post tumor injection (Fig. 20) and TIMs isolated from these mice
displayed significantly higher proinflammatory cytokine mRNA compared to control
mice (Fig. 26). In many cancers, TIMs exhibit deficient expression of NF-κB leading to
impaired iNOS expression and nitric oxide production [229, 230]. Additionally, it has
been observed that TIMs have very high nuclear localization of the NF-κB inhibitory p50
homodimer [231] and defective NF-κB activation in response to LPS and TNFα
stimulation [232]. We observed drastically higher NF-κB p65 activity in TIMs isolated
from MacAMPKα1 KO mice (Fig. 28), indicating that AMPKα1 inhibition alters TIM
gene transcription. Additionally, AMPKα1-deficient TIMs displayed decreased activation
of Akt and CREB (Fig. 29). These data fit with our previous observations that AMPKα1
activation is positively correlated with activation of Akt and increased phosphorylation of
CREB (Fig. 19, [106]). Enhanced CREB activity allows CREB to compete for the
nuclear coactivator CREB-binding protein and leads to reduced activation of NF-κB.
Our studies of LLC tumor growth address tumor growth until 18 days postinjection, when mice were sacrificed. We did not measure tumor growth beyond 18 days,
and thus it is possible that tumors in MacAMPKα1 KO mice had delayed growth, and
may eventually catch up to the tumor growth observed in WT mice. Additionally, we did
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not complete survival studies and it is unknown if MacAMPKα1 KO mice have increased
survival associated with LLC tumor growth compared to WT.
Mice with AMPKα1-deficient macrophages had reduced lung metastasis
compared to control mice (Fig. 22). Macrophages are important in the development of
lung metastasis, and have been shown to condition pre-metastatic tissue for the seeding of
metastatic cancer cells [120]. In some tumor models, infiltrating myeloid cells form
clusters in pre-metastatic tissue, forming what has been termed a “pre-metastatic niche”
[233, 234]. Our studies show that deficiency of macrophage-expressed AMPKα1 results
in decreased lung metastasis. However, the functional phenotype of AMPKα1-deficient
macrophages in the lung is unknown. Furthermore, the role of macrophage-expressed
AMPKα1 on formation of the pre-metastatic niche still needs to be investigated.
Our studies indicate no difference in immune cell infiltration of NK, CD4+, CD8+,
macrophages, and CD11c+ cells in tumors from MacAMPKα1 KO and WT mice (Fig.
24). Our results did indicate that there was higher infiltration of CD19+ cells in tumors of
mice deficient of myeloid AMPKα1. Studies suggest that B cells can contribute to the
immunosuppressive phenotype exhibited by TIMs [235, 236]. B1 cells have been shown
to polarize peritoneal macrophages to an anti-inflammatory phenotype via IL-10
expression [235]. Additionally, B cells have been shown to foster angiogenic and protumor TIM activities through FcRγ-mediated activation [236]. Much is still unknown
regarding the roles of various B cell populations on determination of TIM phenotype.
Additionally, how deficiency of myeloid-AMPKα1 leads to enhanced B cell recruitment
to the tumor still needs to be investigated. One possible explanation is that the tumor
recruits B cells in an attempt to establish a pro-tumor immunosuppressive environment
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and combat the higher pro-inflammatory phenotype exhibited by AMPKα1-deficient
TIMs.
Functional studies are also required to determine if AMPKα1 activity in TIMs
affects the role of B cells in the tumor, as well as the roles of other infiltrating immune
subsets. It is unknown if TIM-expressed AMPKα1 regulates infiltration of Th subsets and
Treg, which are known to foster the immunosuppressive environment in tumors [237].
We observed increased CD8+ T cell infiltration in WT tumors compared to MacAMPKα1
KO tumors (Fig. 24) and it is unknown how AMPKα1 TIM expression contributes to this
accumulation and how these cells are functionally contributing to tumor growth.
It is important to note that because our TIM isolation included positive selection
of CD11b+ tumor-infiltrating cells, we expect to have tumor-infiltrating MDSC in our
“TIM” population. As we saw increased proinflammatory activity in tumor-infiltrating
CD11b+ cells, our studies suggest that MDSC may have a more proinflammatory
phenotype in MacAMPKα1 KO tumors. A more specific isolation is needed in order to
distinguish the MDSC functional phenotype from that of CD11b+ TIMs in MacAMPKα1
KO tumors compared to WT tumors. Additionally, MDSC have a critical role in the
establishment of the immunosuppressive tumor microenvironment and future studies will
address the effect of myeloid-AMPKα1 deficiency on recruitment of MDSC to the tumor
and their functional phenotype within the tumor.
The immunosuppressive tumor microenvironment is considered a major obstacle
to the success of cancer therapies. Herein, we demonstrate that AMPKα1 depletion in
TIMs critically affects their anti-inflammatory phenotype and their efficiency in
promoting LLC tumor growth. Our results indicate the therapeutic potential of AMPKα1
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inhibition as a way to curtail the pro-tumor functions of TIMs and reduce tumor
progression. Furthermore, these data suggest that efforts to treat cancer through activation
of AMPKα1 may detrimentally contribute to TIM immunosuppressive phenotype and
tumor growth.
AMPK activation has been associated with both reduced risk of cancer
development and tumor regression [1]. Many AMPK activators, including metformin
[83], green tea [239], and resveratrol [240] have been shown to reduce cancer risk. The
association of AMPK activation with reduced risk of specific cancers in various
populations is still being investigated. It has been shown that metformin leads to reduced
risk of breast cancer in female diabetic patients [241]. Chronic inflammation has been
associated with increased cancer incidence, and it is possible that AMPK is inhibiting
cancer development through decreasing inflammation [1]. Activation of AMPK has been
shown to also reduce tumor growth, an effect attributed to AMPK inhibition of anabolic
signaling pathways responsible for cell growth [88]. In conditions of limited energy
supply, as is often in the tumor microenvironment, AMPK is activated and inhibits
mTOR activity [67, 242] and lipid synthesis [243, 244], leading to decreased cancer cell
growth. In addition to AMPK’s role in the metabolism of cancer cells, it also likely has
an important role in the regulation of metabolism and inflammation of other cells present
in the tumor. Our results herein demonstrate that AMPKα1 activity in macrophages
contributes to TIM anti-inflammatory activity and tumor growth. These results suggest
that AMPKα1’s role in the tumor may be complicated, and that its activation may
enhance pro-tumor activities in some cells and anti-tumor activities in others. Perhaps
this is not surprising, as the cellular metabolism of transformed cells may be different
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than infiltrating immune cells and, accordingly, AMPK regulation of inflammatory and
metabolic pathways may result in differential regulation of these cell types.
It is likely that AMPK plays different roles in the stages of tumor development
and progression, reflecting the complicated nature of the relationship between
metabolism, inflammation, and cancer. AMPK activation may be beneficial in the
prevention of cancer pathologies associated with chronic inflammation, while in later
stages of cancer progression, it may detrimentally contribute to TIM anti-inflammatory
activity and LLC tumor growth. AMPK inhibition in TIMS may be a valuable therapeutic
strategy to overcome the strong immunosuppression these cells generate. The use of
nanoparticle technology may be of potential use to inhibit AMPK in macrophages,
specifically through utilization of the mannose receptor for macrophage specificity and
an AMPK inhibitor, such as compound C. Much remains to be investigated, but our
studies demonstrate that it will important to consider the effect of AMPKα1 activation in
TIMs when developing cancer therapies.
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CONCLUSIONS AND FUTURE PERSPECTIVES

DCs and macrophages are heterogeneous cells that are involved in both protective
and pathological immune responses. Understanding the mechanisms that govern their
behavior is critical to the understanding and development of effective therapies to treat
many diseases, including autoimmunity and cancer. AMPK has been recognized recently
as a counter-regulator of inflammatory pathways including those induced by TLR and
IFNγ stimulation [96, 106, 163] and fatty acids [107, 108]. Through studies on
macrophage cell lines expressing CA and DN forms of AMPKα1, our lab previously
reported that AMPKα1 inhibits TLR-mediated inflammatory activity [106]. Herein, we
have used AMPKα1-deficient primary cells to evaluate the role of AMPKα1 in APC-T
cell interactions. Our studies show that deficiency of AMPKα1 results in enhanced APC
inflammatory activity in response to LPS and CD154 stimulation (Fig. 5 and Fig. 16) and
contributes to the development of proinflammatory Th1 and Th17 responses (Fig 8-10).
Additionally, we evaluated the role of myeloid cell-expressed AMPKα1 in TIM antiinflammatory activity and its contribution to tumor growth. We demonstrate that
inhibition of AMPKα1 in TIMs enhances their proinflammatory activity (Fig. 26-29) and
results in decreased tumor growth and lung metastasis (Fig. 20-22). Together, our studies
of AMPKα1 in antigen presentation and on AMPKα1 in tumor-macrophage interactions
demonstrate that AMPK is a potent counter-regulator of myeloid inflammatory activity

93

and its activation induces changes in many aspects of myeloid function. These changes
are mediated through differential regulation of NF-κB and Akt - GSK3β – CREB
pathways.
Our results demonstrate a counter-regulatory role for AMPKα1 in the regulation
of myeloid cell and T cell proinflammatory activity. Much is still unknown regarding the
role of AMPKα1 in the regulation of immunity. AMPKα1 may have regulatory roles
regarding the inflammatory activity of other immune cells in addition to macrophages
and T cells, and this still needs to be investigated. Additionally, a recent report showed
that AMPKβ1 leads to an 85% reduction in AMPK activity and counter-regulates
macrophage proinflammatory activity and insulin resistance [108]. Much is still unknown
regarding the role of AMPKβ1 in the regulation of macrophage inflammation and the role
of AMPKβ1 in antigen presentation activities still needs to be investigated.
Our studies and others have identified AMPKα1 is a counter-regulator of
macrophage and DC inflammatory activity and both activation and inhibition of AMPK
may be valuable therapeutic strategies for inflammatory diseases (Fig. 30). Excessive
Th1 and Th17 responses are associated with autoimmune disease and research strategies
include identifying targets that can attenuate these T cell responses. Our results indicate
that AMPKα1 is one such potential target, as AMPKα1 expression in both APC and T
cells leads to reduced IFNγ and IL-17 T cell production in antigen presentation assays
(Figs. 6, 8-9, 30). Indeed, it has been shown that AMPK activation ameliorates
experimental mouse models of autoimmunity, including EAE [98] and EAU [43].
Chronic inflammation has been long associated with increased risk for several cancers,
including lung, and activation of AMPK may reduce systemic inflammation and risk for
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these cancers (Fig. 30). Importantly, the effectiveness of AMPK activation on the
prevention of cancer development may be dependent on the type of cancer and the timing
of treatment or stage of cancer development. There are several readily available
pharmacological and dietary activators of AMPK, as discussed in Chapter 1.
The therapeutic use of inhibitors of AMPKα1 activity also may be worthwhile, as
there are many diseases where an immunosuppressive environment perpetuates
pathology, such as cancer (Fig. 30). Our studies on TIMs from MacAMPKα1 KO mice
indicate that in cancer, inhibition of AMPKα1 activates a proinflammatory immune
response in TIMs that leads to reduced tumor growth. Inhibition of AMPKα1 in TIMs
may be a valuable therapeutic strategy to combat immunosuppressive TIMs that
contribute to tumor growth (Fig. 30). Inhibition of AMPKα1 in DCs may also be a
valuble strategy to combat the tolerogenic phenotype known to be an obstacle to DC
vaccine immunotherapy. It is also possible that inhibition of AMPKα1 may also lead to a
more potent anti-microbial and/or anti-parasite immune response, although this has not
been tested (Fig. 30).
This study is the first to identify AMPKα1 as a mediator of TIM antiinflammatory activity. TIMs isolated from MacAMPKα1 KO mice had increased
phosphorylation of p65 NF-κB (Fig. 28) and expressed higher levels of IL-6 and TNFα
mRNA (Fig. 26). Higher expression of proinflammatory markers in TIMs was associated
with decreased tumor growth. TIMs have a critical role in the development of the
immunosuppressive, pro-tumor environment and identifying mediators of TIM antiinflammatory activity, such as AMPK, is critical for the development of cancer
immunotherapies. Additionally, the extent of myeloid AMPKα1’s influence on the pro-
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and anti-tumor functions of other immune cell populations within the tumor, including
cytotoxic T cells, Treg, and MDSC still needs to be investigated. It is unknown if
AMPKα1 also plays a counter-regulatory role in the inflammatory activity of tumor
infiltrating T cells. Our laboratory has mice deficient in CD4 cell-expressed AMPKα1
that could be utilized to determine the role of AMPKα1 in CD4+ cells in tumor growth
and metastasis.
The anti-inflammatory effect of AMPK on leukocyte behavior has been
associated with the involvement of AMPK in cellular metabolism. Recent reports suggest
that AMPK represses the metabolic switch from oxidative phosphorylation to glycolysis
that occurs when cells become inflammatory. As described in two recent reviews from
the lab of Graham Hardie [93, 245], resting and naïve immune cells generally use
oxidative phosphorylation to generate ATP and when stimulated with proinflammatory
stimuli (cytokines, TLRs, antigen presentation), switch to aerobic glycolysis for
generation of ATP [94-96]. It has been observed that treatment with a glycolytic inhibitor
causes proinflammatory Th17 cells to exhibit qualities more like anti-inflammatory
Tregs, suggesting that metabolic cues are involved in the regulation of the glycolytic
switch [94]. It is thought that increased rates of glycolysis provide a swift, yet inefficient,
source of energy for the cell to become more inflammatory. AMPK activation through
AICAR antagonizes the LPS-induced switch to glycolysis in DCs [96]. Additionally, T
cells isolated from AMPKα1-/- mice display elevated levels of glycolysis [116]. AMPK
inhibits protein synthesis through TORC1 [67, 68], and it has been proposed that AMPK
mediates the glycolytic switch through repressing expression of the transcription factor
hypoxia-inducible factor-1α (HIF1α) through TORC1 inhibition [245]. HIF1α expression
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drives the production of glycolytic enzymes and its inhibition could then repress the
glycolytic switch [245].
Our findings regarding AMPKα1’s role in regulation of myeloid inflammatory
activity raise many questions regarding the role of AMPKα1 in regulation of the
glycolytic switch. AMPKα1 antagonizes CD154-induced proinflammatory signaling and
cytokine production and it is unknown if CD154 stimulation is associated with a
transition from oxidative to glycolytic metabolism. Additionally, AMPKα1’s ability to
suppress the switch to glycolysis in response to CD154 still needs to be investigated. Our
studies show that AMPKα1 regulates the anti-inflammatory activity in TIMs and it is
unknown if AMPKα1 represses glycolytic activity in TIMs and thereby contributes to
their anti-inflammatory phenotype. The metabolic switch to glycolysis was first observed
in proliferating cancer cells and was termed the ‘Warburg effect,’ and the potential ability
of AMPKα1 to induce an anti-Warburg effect in cancer is one argument for using AMPK
activators to treat cancer patients [245].
As we learn more about the metabolic profile of tumor-infiltrating immune cell
subsets, it will be important to consider the impact AMPKα1 activation may have on their
inflammatory phenotype and role in the tumor microenvironment. It is also important to
consider that aside from its regulatory role in cell metabolism, AMPKα1 activity
modulates numerous signaling pathways that influence cell behavior and gene
transcription. Given its clear role in the regulation of both metabolism and inflammation,
AMPKα1 has great potential as a target for the treatment of many diseases.

97

Figure 30. Both activation and inhibition of myeloid AMPKα1 may be useful
therapeutic strategies. Activation of AMPKα1 in myeloid cells leads to decreased proinflammatory activity including increased Akt - GSK3β – CREB signaling and IL-10
production. AMPKα1 activation may be a useful therapeutic strategy for the treatment of
diseases exacerbated by inflammation, such as autoimmune disease cancer-causing
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chronic inflammation. Inhibition of AMPKα1 activity in myeloid cells leads to increased
proinflammatory activity including increased Th1 and Th17 T cell responses, NF-κB and
MAPK signaling, costimulatory molecule expression, and IL-6 and TNF-α cytokine
production. AMPKα1 inhibition may be a useful therapeutic strategy to increase the
inflammatory activity of immunosuppressive TIMs and tolerogenic DC in vaccine
immunotherapy. Additionally, AMPKα1 inhibition may lead to a more potent antimicrobial and anti-parasite immune response.
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